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The theme of this dissertation focuses on developing statistical models to learn progression
dynamics and mechanisms of neuropsychiatric disorders using data from various domains. Due
to limited knowledge about the underlying pathological processes in neurological disorders, it
remains a challenge to establish reliable diagnostic criteria and predict disease prognosis in the
presence of substantial phenotypic heterogeneity. As a result, current diagnosis and treatment of
neurological disorders often rely on late-stage clinical symptoms, which poses barriers for de-
veloping effective interventions at the premanifest stage. It is crucial to characterize the temporal
disease progression course and study the underlying mechanisms using clinical assessments, blood
biomarkers, and neuroimaging biomarkers to evaluate disease stages, identify markers that are use-
ful for early clinical diagnosis, compare or monitor treatment effects and accelerate drug discovery.
We propose three projects to tackle challenges in leveraging multi-domain biomarkers and clin-
ical symptoms to learn disease dynamics and progression of neurological disorders: (1) A nonlin-
ear mixture model with subject-specific random inflection points to jointly fit multiple longitudinal
markers and estimate marker progression trajectories in a single modality; (2) A multi-layer expo-
nential family factor model integrating multi-domain data to learn lower-dimensional latent space
of disease impairment and fully map disease risk and progression; (3) A latent state space model
that jointly analyzes multi-channel EEG signals and learns dynamics of different sources corre-
sponding to brain cortical activities. In addition, motivated by the ongoing COVID-19 pandemic,
we propose a parsimonious survival-convolution model to predict daily new cases and estimate the
time-varying reproduction numbers to evaluate effects of mitigation strategies.
In the first project, we propose a nonlinear mixture model with random time shifts to jointly
estimate long-term progression trajectories using multivariate discrete longitudinal outcomes. The
model can identify early disease markers, their orders of occurrence, and the rates of impairment.
Specifically, a latent binary variable representing disease susceptibility status incorporates subject
covariates (e.g., biological measures) in the mixture model to capture between-subject heterogene-
ity. Measures of disease impairment for susceptible patients are modeled jointly under the expo-
nential family framework. Our model allows for subject-specific and marker-specific inflection
points associated with patients’ characteristics (e.g., genetic mutation) to indicate a critical time
when the fastest degeneration occurs. Furthermore, it uses subject-specific latent scores shared
among markers to improve efficiency. The model is estimated using an EM algorithm. Extensive
simulation studies are conducted to demonstrate validity of the proposed method and algorithm.
Lastly, we apply our method to the Parkinson’s Progression Markers Initiative (PPMI), and show
utility to identify early disease signs and compare clinical symptomatology for the genetic form of
Parkinson’s Disease (PD) and idiopathic PD.
In the second project, we tackle challenges to leverage multi-domain markers to learn early
disease progression of neurological disorders. We propose to integrate heterogeneous types of
measures from multiple domains (e.g., discrete clinical symptoms, ordinal cognitive markers, con-
tinuous neuroimaging and blood biomarkers) using a hierarchical Multi-layer Exponential Family
Factor (MEFF) model, where the observations follow exponential family distributions with lower-
dimensional latent factors. The latent factors are decomposed into shared factors across multiple
domains and domain-specific factors, where the shared factors provide robust information to per-
form behavioral phenotyping and partition patients into clinically meaningful and biologically ho-
mogeneous subgroups. Domain-specific factors capture the remaining unique variations for each
domain. The MEFF model also captures the nonlinear trajectory of disease progression and or-
der critical events of neurodegeneration measured by each marker. To overcome computational
challenges, we fit our model by approximate inference techniques for large-scale data. We ap-
ply the developed method to Parkinson’s Progression Markers Initiative (PPMI) data to integrate
biological, clinical and cognitive markers arising from heterogeneous distributions. The model
learns lower-dimensional representations of Parkinson’s disease and the temporal ordering of the
neurodegeneration of PD.
In the third project, we propose methods that can be used to analyze multi-channel electroen-
cephalogram (EEG) signals intensively measured at a high temporal resolution. Modern neu-
roimaging technologies have substantially advanced the measurement of brain activities. EEG as a
non-invasive neuroimaging technique measures changes in electrical voltage on the scalp induced
by cortical activities. With its high temporal resolution, EEG has emerged as an increasingly
useful tool to study brain connectivity. Challenges with modeling EEG signals of complex brain
activities include interactions among unknown sources, low signal-to-noise ratio and substantial
between-subject heterogeneity. In this work, we propose a state space model that jointly ana-
lyzes multi-channel EEG signals and learns dynamics of different sources corresponding to brain
cortical activities. Our model borrows strength from spatially correlated measurements and uses
low-dimensional latent sources to explain all observed channels. The model can account for pa-
tient heterogeneity and quantify the effect of a subject’s covariates on the latent space. The EM
algorithm, Kalman filtering, and bootstrap resampling are used to fit the state space model and
provide comparisons between patient diagnostic groups. We apply the developed approach to a
case-control study of alcoholism and reveal significant attenuation of brain activities in response
to visual stimuli in alcoholic subjects compared to healthy controls.
Lastly, motivated by the ongoing COVID-19 pandemic, we propose a robust and parsimonious
survival-convolution model aiming to predict COVID-19 disease course and compare effectiveness
of mitigation measures across countries to inform policy decision making. We account for trans-
mission during a pre-symptomatic incubation period and use a time-varying effective reproduction
number (Rt) to reflect the temporal trend of transmission and change in response to a public health
intervention. We estimate the intervention effect on reducing the infection rate using a natural ex-
periment design and quantify uncertainty by permutation. In China and South Korea, we predicted
the entire disease epidemic using only early phase data (two to three weeks after the outbreak). A
fast rate of decline inRt was observed and adopting mitigation strategies early in the epidemic was
effective in reducing the infection rate in these two countries. The nationwide lockdown in Italy
did not accelerate the speed at which the infection rate decreases. In the United States, Rt signifi-
cantly decreased during a 2-week period after the declaration of national emergency, but declines
at a much slower rate afterwards. If the trend continues after May 1, COVID-19 may be controlled
by late July. However, a loss of temporal effect (e.g., due to relaxing mitigation measures after
May 1) could lead to a long delay in controlling the epidemic.
Key Words: Nonlinear mixture model, Inflection points, Factor models, Multivariate longitudinal
data, Variational inference, Patient heterogeneity, Disease progression, Parkinson’s disease, Multi-
channel EEG signals, State space models, COVID-19
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Progressive neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Dis-
ease (PD) have complex pathological mechanisms and can lead to severe behavioral and cognitive
impairment over life time. Due to a lack of gold standard biomarkers, current diagnosis of neuro-
logical disorders often relies on late-stage clinical symptoms, which poses barriers for developing
preventive care at the premanifest stage (Gelb et al., 1999). Furthermore, the highly variable dis-
ease course and heterogeneity among patients make it difficult to construct models that can accu-
rately describe the underlying disease progression for the entire population while also considering
subject-specific variability.
Clinical, biological and neuroimaging measures have been suggested as disease markers and
their trajectory patterns over time can reflect the underlying disease progression (Dubois et al.,
2014). Recent research has shown that various domains of markers can be used to characterize
long-term disease progression and provide valuable diagnostic evidence at an early stage. For ex-
ample, in our motivating study of the Parkinson’s Progression Markers Initiative (PPMI), some
subtle motor and non-motor signs are present in PD patients early in their disease course (Noyce
et al., 2016). Another example is the Neurobiological Predictors of Huntington’s Disease study
(PREDICT-HD), where it has been shown that neuroimaging, motor and behavioral measures are
strong indicators of disease deterioration at early age (Paulsen et al., 2014). However, since differ-
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ent markers deteriorate at different rates and reach their maximum rates of change in an ordered,
age-dependent manner (Jack Jr et al., 2010), not all of the markers contain useful information of
disease progression at all ages. It is crucial to model marker trajectories in order to estimate their
marker-specific progression rates and understand the time-dependent ordering of relevant markers
to identify the most informative set. Such information is useful for early diagnosis and assessment
of disease impairment at any age of a subject’s life time. In addition, due to complex disease
pathology, there is substantial heterogeneity in symptom manifestation and progression trajecto-
ries among patients. Data from a single domain will not be sufficient for comprehensive charac-
terization of disease risk and progression. Instead, integrating multi-domain markers through joint
modeling will be necessary to fully map the disease progression, understand the interplay among
different domains and capture patient heterogeneity.
In addition to resourceful clinical and behavioral data for studying disease progression in neu-
rological disorders, modern neuroimaging technologies have also substantially advanced measure-
ments of brain signals to learn dynamics of brain activities. For example, electroencephalogram
(EEG) is a neuroimaging technique that measures changes in electrical voltages on the scalp in-
duced by brain cortical activities and can be used as a type biomarker for neurological disorders.
EEG allows for capturing fast-changing brain activities with high temporal resolution, and its non-
invasive nature has made EEG an increasingly useful tool to explore brain functions. However, it
is highly challenging to analyze multi-channel EEG time-series data that measures complex brain
activities. For example, EEG has an inadequate spatial resolution. The observed EEG signals on
the scalp are often a mixture of unknown underlying brain sources. As a result, directly modeling
observed signals measured from scalp electrodes without considering the underlying brain sources
will not be adequate.
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In the following dissertation, we develop three statistical methods for modeling disease pro-
gression and learning mechanisms of neuropsychiatric disorders addressing the above challenges.
In Chapter 2, we propose a nonlinear mixture model to jointly fit multiple ordinal markers and
estimate marker progression trajectories and their order of occurrence to assist early diagnosis. In
Chapter 3, we extend the model in Chapter 2 to incorporate different data types and develop a
multi-layer exponential family factor model to integrate multi-domain data and fully map disease
risk and progression. Chapter 4 learns dynamics of brain sources incorporating subject characteris-
tics by jointly analyzing multi-channel EEG signals using a state space model. As another project
motivated by the ongoing COVID-19 pandemic, Chapter 5 presents a survival-convolution model
to model daily new cases and estimate the time-varying reproduction numbers that can be used to
evaluate the effectiveness of various mitigation interventions.
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Chapter 2
Nonlinear Mixture Models for Identifying Early Markers of Neurological
Diseases
2.1 Introduction
Natural history studies of neurological diseases such as PREDICT-HD and PPMI often collect
longitudinal data of a comprehensive set of clinical measures or instruments. For example, a
primary measure in the PPMI study include different motor and non-motor functions evaluated
by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
MDS-UPDRS describes PD disability using a collection of ordinal items, each with a 0 − 4 scale
(Goetz et al., 2008). Summary measures such as total motor score are created from individual
variables/items in the UPDRS to assess broad changes in patients. However, analyzing patterns
of early changes indicated by individual items in an instrument may reveal a much more detailed
profile of patient’s health state which is missed in a summary measure. Therefore, in this work
we will focus on methods and analysis of individual items to capture differential time-dependent
patterns among domains measured by an instrument.
Since distinct domains of patient’s health functions deteriorate at different rates, the observed
outcomes of each item can be unbalanced and sparse among patients. Joint modeling is required
to pool information across items and patients in order to increase the accuracy and efficiency of
4
estimation. Meanwhile, due to disease heterogeneity, it is also important to account for individual
differences between subjects. Generalized linear mixed models (GLMM) are commonly used for
ordinal longitudinal data, but most are applied for univariate outcomes. Although extensions to
multivariate GLMM is proposed (Jaffa et al., 2016), jointly fitting a large number of discrete out-
comes with random effects is numerically challenging because of nonlinearity of the link function
and required integration of the random effects when computing the likelihood. Generic softwares
for fitting generalized mixed models may not converge and can lead to rather poor performance in
practice as observed in our numeric examples (Section 2.3.1.1). When the observations in some
categories are rare, the numeric instability may be even more pronounce.
Another type of model that can handle multiple ordinal markers while also considering some
subject-specific latent traits lies in the field of item response theory (IRT) (DeMars, 2010). IRT
refers to a family of latent variable models that explain the relationship between some continuous
unobserved trait of a subject and a group of items governed by the trait. It allows joint estimation
of distribution of different markers with respect to a latent subject-specific trait, and provides a
personal standardized score for the trait. For example, (Ueckert et al., 2014) applied IRT model
to investigate the relationship between cognitive test items for AD and the underlying cognitive
disability. The binary outcome measured success or failure of a task. Similar to other IRT models,
logit of the probability of success was modeled as a linear form of the latent cognitive disabil-
ity. The result gave each outcome an estimated discrimination parameter relating to the rate at
which the probability of success changed with respect to the latent trait and an estimated severity
parameter showing the value of the latent trait where the probability changed the most rapidly (in-
flection point). This inflection point is of great interest since it indicates the point beyond which
the outcome progression decelerated. IRT models mainly focus on dichotomized outcomes with
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cross-sectional data. Some extensions to accommodate more complex applications include Mu-
raki (1992) that proposed Generalized Partial Credit Model (GPCM) to analyze ordinal categorical
items. Ueckert et al. (2014) also introduced an additional step to incorporate an existing IRT
model into an external longitudinal data analysis. However, these methods do not incorporate
subject-specific covariates, require assumptions on prior distribution, more computational burden,
and experiences of convergence diagnostics.
In this work, we propose a nonlinear mixture model with random, subject-specific latent lo-
cation shifts. Our model falls under the more general class of shape invariant models (Brumback
and Lindstrom, 2004), but with tailored functional form for applications to neurological disorders.
Given latent effects, the model has a sigmoidal shape over time, which is consistent with the most
widely recognized model for AD progression proposed in Jack Jr et al. (2010) and also observed
for other diseases (Ross et al., 2014). It also flexibly accounts for between-subject variation around
the location of the most rapid progression (i.e., inflection point of a sigmoidal curve). More specif-
ically, we model distributions of ordinal disease markers as a mixture component using a binary
indicator to account for non-susceptible population (i.e., population who are not at risk of AD or
PD during the life time). For the susceptible population, the outcomes naturally follow a sigmoidal
shape with respect to time as suggested in the literature (Jack Jr et al., 2010). To be parsimonious,
we adopt an adjacent-category logit model (ACL) for severity levels of the ordinal markers. We
use a subject-specific latent score that depends on covariates (e.g., genetic variants) as a random
shift on their time to reaching inflection points. These latent shifts accommodate both between-
subject heterogeneity in terms of disease progression course and longitudinal repeated measures
of a subject. In our model, the inflection point with information of disease severity is both marker-
and subject-specific. Baseline characteristics of subjects are incorporated in the model through the
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binary susceptibility indicator and the subject-specific latent score.
We use the EM algorithm to obtain parameter estimates and compute conditional expectations
for prediction. Compared to existing methods, our proposed model is flexible enough to allow
for different progression rates and population averaged inflection points for different markers in
order to understand the time-dependent ordering of markers and facilitate early diagnosis. With
baseline characteristics incorporated, we can compare effects of characteristics on disease progres-
sion. In addition, the subject-specific latent score enhances the accuracy for predicting a patient’s
unobserved outcomes for a specific marker based on previous records. Using joint modeling, in-
formation across various markers can be borrowed to increase power.
We organize the rest of this paper as follows. In Section 2.2, we present the proposed model and
discuss the estimation process using the EM algorithm. In Section 2.3, the first simulation study
investigates performance of the parameter estimation in three different scenarios. The second
simulation compares the proposed model with a multivariate GLMM in terms of the prediction
accuracy. In Section 2.4, we apply the proposed method to the motivating PPMI study with a
focus on the analyses of the most informative markers. Similar to the second simulation study,
prediction accuracy of a subject’s future observation given previous measurements is compared
using our model and a multivariate GLMM on the PPMI. We also compare disease progression
rates from two different genetic cohorts to examine the impact of a genetic risk factor on the




2.2.1 Nonlinear Mixture Model With Random Location Shifts
Let Yijk be the ordinal symptom outcome for the ith subject measured at the jth follow-up time
for the kth marker (e.g., Freezing of Gait, Postural Stability in MDS-UPDRS), where i = 1, ..., N ,
k = 1, ..., K. Each patient can have a different number of repeated measures nik for the kth marker.
The observed symptom outcome Yijk takes integer values from 1 to C, where Yijk = 1 indicates
absence of symptom and a larger value indicates more severe impairment. Our proposed model is
given by
Yijk = Qik + (1−Qik)Hijk, Yijk = 1, · · · , C, Qik = 0, 1, Hijk = 1, · · · , C,
where the population consists of a mixture of individuals With a binary latent variable Qik ac-
counting for the long-term non-susceptibility status. When Qik = 1, the subject is resilient (not
susceptible) to pathological changes manifested through the kth marker during the life course and
thus will not present clinical symptoms (Yijk ≡ 1 for all j = 1, ..., nik). When Qik = 0, the
subject is susceptible to pathological changes and may manifest a higher level of impairment (e.g.,
Hijk > 1). The probability of possessing resilience is assumed to be associated with the baseline
covariatesXi = [1,Zi] as
logitP (Qik = 1|Zi) = ηk>Xi.
As a result, the population with the normal clinical state Yijk = 1 is consisted of patients who
are resilient (Qik = 1) and who are susceptible but without detectable clinical signs (Qik = 0,
Hijk = 1):






P (Hijk = 1|Qik = 0).
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When Qik = 0, ACL is used to model the severity of ordinal clinical symptoms denoted by Hijk.
The conditional probability ratio (in log scale) of having an outcome level c over a more severe
level c+ 1 for a susceptible ith patient with age tijk is formulated as
log
P (Hijk = c|dik)
P (Hijk = c+ 1|dik)
= bk(tijk − dik) + δc, c = 1, ..., C − 1,
or alternatively,












(C − c′)bk(tijk − dik) +
∑C−1
l=c′ δl
) , c = 1, ..., C,
where bk indicates the marker-specific rate of disease progression. Since the probability of having
an outcome of level c or less decreases as age tijk increases, bk is constrained to be negative. In the
absence of δc, dik is the inflection point age that a susceptible patient with an outcome level c has to
pass in order to have a higher chance to reach the next outcome level c+ 1. It is also the age when
the probability curve P (Hijk ≤ c) decreases the fastest with respect to tijk. Since this inflection
point age may differ for different successive outcome levels, we introduce the parameter δc for
each level. The inflection point age with the same interpretation is then modified as dik− δc/bk. To
ensure identifiability, δ1 is fixed to be 0 and only δ2, ..., δC−1 are free parameters to be estimated.
In the model, a critical landmark point is dik, since it is the age when the deterioration from a
normal state occurs at the maximal rate. To investigate the temporal ordering of the K markers as
the disease progresses, we further assume that dik can be modeled as a function of subject-specific
random effects,
dik = µk + χkWi, Wi ∼ N(θ>Zi, 1), (2.1)
where the latent variable Wi is shared across the K markers. This latent variable shifts an individ-
uals’ inflection point to an earlier or later age according to observed covariates Zi and unobserved
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random effects. Thus, an individual may experience symptom at an earlier or later age. Assume
that continuous covariates in Zi are standardized such that the reference population will have
Zi = 0. In model (2.1), µk is the expected inflection point age when a subject in the reference
population deteriorates the fastest from a normal state. χk is a non-negative parameter that quanti-
fies the effect of Wi on dik. The term χkWi is then a subject-specific and marker-specific random
shift from µk. A subject with a larger latent score Wi or a marker with a large χk will have a larger
value of dik, which represents that disease deterioration manifests a severe symptom at an earlier
age.
The average inflection point, µk − δc/bk, represents the age when the level c clinical sign
changes the most rapidly and when deterioration is the easiest to detect. Therefore, it may indi-
cate the optimal window for treatment intervention when the management of disease impairment
is more critical. Furthermore, since dik captures both maker- and subject-specific shifts from the
average inflection point, it allows identifying the earliest manifested markers for different individ-
uals. In terms of statistical power, using a latent variableWi shared across markers provides higher
efficiency to predict inflection points by borrowing information from all markers. We will illustrate
these benefits in simulations and real world applications.
2.2.2 Estimation Using the EM Algorithm
The EM algorithm is often used to estimate parameters when there are latent variables in the model.
The graphical model in Figure 2.1 shows the relating parameters, random variables and dependen-
cies that we describe in Section 2.2.1. In this model, age, baseline characteristics and symptom
outcomes of subjects are the observed variables shaded in gray, denoted as O = (X, t,Y ). The re-














Figure 2.1: Graph of the proposed nonlinear mixture model. The nodes shaded in red (Qik, Hijk
and Wi) are the latent unobserved variables while the nodes shaded in gray (Xi,Zi, Yijk and tijk)
are the observed variables.
random variables shaded in red. Our goal is to estimate the parameters Θ that can maximize the
observed data log-likelihood ln(Θ;O). By conditional independence in Figure 2.1, the complete
data log-likelihood ln(Θ;O, Q,W ) assuming the latent variables are observed is as follows:
















logf(Yijk|Qik,Wi) + logf(Qik) + logf(Wi)
}
,
where we denote γk = (bkµk, bk)>, t̃ijk = (−1, tijk)> and χ̃k = −bkχk to obtain each term

































To implement the EM algorithm, we initialize parameters at reasonable starting values and de-
note the current parameter values as Θ(t). In the E-step, we calculate the estimated conditional
expectation of the complete log-likelihood E(ln(Θ(t);O, Q,W )|O) given the observed data and
current parameters. In the M-step, we obtain the updated parameters Θ(t+1) by maximum like-
lihood estimates (MLE) of the conditional expectations in the E-step. It can be shown that the
observed data log-likelihood ln(Θ;O) is guaranteed to increase after each iteration. We iterate
between E-step and M-step until convergence.
Specifically, the key step of evaluating E(ln(Θ(t);O, Q,W )|O) is to evaluate the conditional
expectation of Q and W . Denote the conditional expectation and the conditional probability
given O and Θ(t) by Ê(·) and P̂ (·) respectively. It is straightforward to obtain P̂ (Qik = 1|Wi)












g(Wi)P̂ (Wi)[1− P̂ (Qik = 1|Wi)]dWi,
where g(·) can be any arbitrary functions ofWi. Then we obtain the values ofE(ln(Θ(t);O, Q,W )|O)
by replacing the quantities involving latent variables in ln(Θ;O, Q,W ) with the above condi-
tional expectations. We derive the detailed results for the E-step in Appendix A.1.
Next, in the M-step we update all the parameters Θ(t) by maximizing the expected complete
data log-likelihood, E(ln(Θ(t);O, Q,W )|O) (Appendix A.1). Several parameters have closed




















Since this is the same as the estimating equation for the logistic regression, we can obtain MLE for
ηk by fitting a logistic regression with outcomes replaced by Ê(Qik).
For γk, χ̃k and δc, the root of the score function fromE(ln(Θ(t);O, Q,W )|O) has no analytic
form. Alternatively, we can obtain the Hessian matrix from E(ln(Θ(t);O, Q,W )|O) and apply
one-step Newton-Raphson to approximate the solution. If treating δ2, ..., δC−1 as fixed and known
constants (δ1=0), only the Hessian matrix Hn(γk, χ̃k) of dimension 3 × 3 needs to be computed.
Its value can be obtained independently for each marker since (γk, χ̃k) is conditional independent
of (γk′ , χ̃k′) for k 6= k′ given the observed data. However, considering δ together with (γk′ , χ̃k′)
requires evaluating the Hessian matrixHn(γ, χ̃, δ) of dimension (3k+(C−2))×(3k+(C−2)) be-
cause the conditional independence between (γk, χ̃k) and (γk′ , χ̃k′) vanishes with δ added. Invert-
ing a large Hessian matrix reduces computational speed. Instead, we adopt an iterative procedure
in line with coordinate descent. In the first M-step, we evaluate sn(γk(t), χ̃
(t)




for each k = 1, ..., K treating δ(t) in the current iteration as fixed and known. Then we update these
estimated parameters to obtain γk(t+1) and χ̃
(t+1)
k using one-step Newton-Raphson. In the second
E-step, we calculate the conditional expectation E(ln(Θ(t);O, Q,W )|O) with the updated pa-
rameters γk(t+1) and χ̃
(t+1)




k as fixed and known in the second M-step when evaluating sn(δ
(t)) andHn(δ(t)) for obtaining




We conduct simulation studies closely based on the PPMI study (details described in Section
2.3.1.1) to assess the performance of our proposed model. It consists of two parts. The first
part focuses on parameter estimation and the second part compares the prediction accuracy of the
proposed model with a multivariate GLMM on predicting future outcomes given previous obser-
vations. We summarize the estimation results and illustrate the advantage of our proposed model
on prediction.
2.3.1 Parameter Estimation
To examine the parameter estimation, we simulate N = 200 and N = 400 subjects who share
the same distribution of baseline covariates as the PD patients in the PPMI study cohorts. The
number of repeated measures also imitate the pattern in the study where 19% of them have only
baseline measurements and 52% of them have 7 to 15 repeated measures. The baseline covariates
Zi include gender and standardized baseline age. For simplicity, Xi is the same as Zi except for
an additional column for intercept. The outcome Yijk has four levels similar to MDS-UPDRS with
1 for Normal, 2 for Slight, 3 for Mild and 4 for Moderate or Severe levels. To explore a complete
simulation setting, we simulate a total of 10 markers each with a combination of different parameter
values. The true parameter values in each scenario are presented in Table A.2 to A.4 (Appendix
A.2). For example, the rate of progression bk ranges from −0.05 to −0.6, the average inflection
point parameter µk takes values in 50, 60, 70 and χk, ranges from 0 to 10. Different from bk, µk, χk
and ηk that have maker-specific values, we assume that θ = (−1, 2)> and (δ2, δ3) = (2, 3) are the
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parameters shared across the 10 markers according to our model generative mechanism. This leads
to 6 parameters for each marker and 4 parameters shared across markers.
This simulation study assesses the model performance on parameter estimation in three sce-
narios. Scenario I simulates 200 patients using the process described in Section 2.2.1. Using the
prespecified parameters, we generate values forWi,Qik andHijk to obtain the final observed obser-
vations Yijk. Given the observed outcomes, baseline covariates and follow-up time, our proposed
model can provide parameter estimates by jointly modeling all the 10 markers. To investigate the
effect of sample size on model performance, Scenario II increases the sample size to simulate 400
patients and implements the same joint model. Scenario III generates data for 400 patients un-
der the same model, but analyze each outcome separately to compare with the joint modeling in
Scenario II. In this scenario, we report the estimators of θ and δ as the averages of individually
estimated values across 10 markers. Since the analysis in Scenario III does not make use of the
shared information across markers, we expect a lower efficiency especially for the shared param-
eters. We use bootstrap to compute standard errors and confidence intervals with 200 bootstrap
replicates and repeat the simulations 100 times.
2.3.1 Prediction of a Future Observation
To assess prediction performance, we follow our proposed model structure (Figure 2.1) to simulate
800 patients each with at least two measurements to be consistent with the sample size of the
PPMI data (about 800 patients). Each simulated data set is split into a test data set that contains
the last observation of all the patients and a training set that contains all previous observations. We
apply our estimation procedure (Section 2.2.2) on the training set to estimate the parameters for
10 symptom markers jointly. With the estimated parameters, we can compute Ê(Wi) and Ê(Qik)
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given the observed training data using the derived formulas (Appendix A.1). These two conditional
expectations serve as estimated values forWi and P (Qik = 1) respectively. Therefore, we can plug
in Ê(Wi) and Ê(Qik) to get
P̃ (Yijk = 1) = Ê(Qik) + (1− Ê(Qik))P̃ (Hijk = 1),
P̃ (Yijk = c) = P̃ (Hijk = c) for c > 1,












(C − c′)bk(tijkµk − χkÊ(Wi)) +
∑C−1
l=c′ δl
) , c = 1, ..., C
where P̃ (·) is the predicted probabilities of a patient having outcomes Yijk = 1, 2, ..., 4. The
level that corresponds to the highest conditional probability will be the estimated outcome for the
patient.
The prediction result is compared with that from fitting a GLMM model. To make it compa-
rable with our joint model, we applied a multivariate GLMM model on the ten outcomes jointly,
with only one set of subject-specific random intercepts shared across the markers. This model
formulation is called shared random intercept (SHRI) by Jaffa et al. (2016). The model with ACL
link and a random intercept is fitted by using the R package vcrpart (Buergin and Ritschard, 2018).
The fixed effects contain baseline covariates (gender, baseline age) and age of measurement (tijk).
To allow for marker-specific slopes, the fixed-effect model also include the 9 marker indicators
as well as their interactions with baseline covariates and tijk. Our result compares the prediction




In Table A.2 to A.4 in the appendix, we summarize the parameter estimates for all markers in
the three scenarios respectively. In each table, we report the mean (Estimate) and the standard
deviation (Empirical s.d) of the estimates across the 100 simulated data sets. The bootstrap s.d is
obtained by calculating the standard deviation of the estimates from 200 bootstrap replicates for
each of the data set and taking an average across the 100 data sets. A 95% bootstrap confidence
interval (CI) is obtained from the 200 replicates and a coverage probability is reported over 100
simulations.
As we can see from Table A.2 to A.4, the biases of the estimators are small in Scenario I and
II when the models are estimated jointly. However, in Scenario III when the model is estimated
individually for each marker, the biases for χ, θ and δ are relatively larger. The empirical s.d is
very close to the bootstrap s.d for most of the parameters as expected. The bootstrap CI coverage
in Scenario I and II is very close to 95%. In contrast, the coverage in Scenario III (Table A.4) is
less desirable, especially for χ1 in Marker 1, b3 and χ3 in Marker 3, and the shared parameter θ, δ.
We select some typical markers that cover different ranges of the true parameter values to
visualize the performance in the three scenarios. Figure 2.2 shows the box plots of the estimates
for the markers with red horizontal lines representing the true parameter values. In this figure, we
see that as the sample size increases from 200 in Scenario I to 400 in Scenario II, all the parameter
estimates are more efficient and with smaller biases. Although it is not shown in the figure, the
estimates with sample size increasing to 800 have the least biases and standard error.
Results from Scenario III are displayed in blue. Recall that in this scenario, individual markers
are analyzed separately. As a result, the estimation for Wi that depends on shared information
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across markers is worse than joint modeling. These inaccurate estimates of Wi will further affect
the estimation for all the parameters other than η. It is evident from Figure 2.2 that the estimation
for χ and b have either higher bias or larger variance or both compared with those in Scenario
II. Similarly, estimation performance for the shared parameters θ and δ is expected to be worse
in Scenario III, which is confirmed in the figure. Estimates of µ have more complicated patterns.
When the true value of χk is small as is the case for the 3rd and 9th marker, the estimation of µk is
worse than in Scenario II. However, when χk has a larger true value such as 5 or 10 in the 4th and
8th marker, the estimation is better than that in the joint models. For parameter η, the estimation
accuracy and efficiency are almost the same as those in Scenario II. This is because estimating ηk
only relies on the conditional expectation of Qik given the observed data, which does not directly
depend on the estimation of Wi. Therefore, whether or not using the shared information does not
have a significant effect on estimation for η.
Prediction of an individual’s last observation given previous measurements is evaluated in terms
of the proportion of the observations that are predicted correctly (Accuracy), the mean absolute
difference (MAE) and square root of the mean squared difference (RMSE) between the predicted
and the true outcomes. Table 2.1 shows the averaged results of the prediction accuracy, MAE and
RMSE from the 100 simulated data sets. We observe that compared with the multivariate GLMM,
our proposed joint model has a higher prediction accuracy, lower MAE and MSE overall.
2.4 Applications to the PPMI Study
The PPMI is a large international study that aims to identity biomarkers of PD progression with
patients who are at an early stage in their disease course Irwin et al. (2013). The patient cohort
consists of 423 de novo PD subjects with diagnosis within two years who have not taken PD med-
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Figure 2.2: Box plots for estimates of the selective markers in three scenarios using the 100 simu-
lated data sets. The red horizontal lines represent the true parameter values. The central rectangle
box spans the first quartile to the third quartile with the band inside the box showing the median.
The two ends of the whiskers show the 2.5% and 97.5% quantile values. θ and δ are the parameters
estimated across the 10 markers for Scenario I and II. For Scenario III using univariate proposed
models, we report the estimators of θ and δ as the averages of individually estimated values across
10 markers. All the other parameters have distinct values for different markers.
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Table 2.1: Performance for predicting the last observation for each of the 10 symptom outcomes
in the simulation study comparing the proposed joint model with a multivariate GLMM∗
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10
Multivariate
GLMM
Accuracy 0.249 0.444 0.741 0.549 0.654 0.807 0.614 0.606 0.692 0.597
MAE 1.222 0.813 0.592 1.120 0.796 0.517 0.901 1.083 0.803 1.185
RMSE 1.534 1.199 1.248 1.745 1.442 1.214 1.527 1.765 1.454 1.875
Proposed
Model
Accuracy 0.524 0.596 0.866 0.800 0.821 0.929 0.793 0.872 0.886 0.909
MAE 0.562 0.449 0.216 0.343 0.280 0.146 0.317 0.270 0.207 0.243
RMSE 0.859 0.739 0.667 0.857 0.738 0.603 0.783 0.821 0.687 0.832
∗ The prediction performance is measured in terms of the proportion of corrected predicted observations (Accu-
racy), the mean absolute difference (MAE) and square root of the mean squared difference (MSE) between the
predicted and the true outcomes. The prediction performance is evaluated for each of the 100 simulated data sets
and the average results are reported.
ications, 183 genetic cohort PD subjects who have a genetic mutation in LRRK2, GBA, or SNCA,
and 187 genetic registry PD subjects who are evaluated at less frequent intervals to augment and
broaden the follow-up periods of PD subjects. Our application focuses on these 793 patients who
had repeated measurements of MDS-UPDRS symptom outcomes. In the study period, 19% of
them have only baseline measurements and 52% of them have 7 to 15 repeated measures. The me-
dian length of follow-up time is 4 years among those who have at least one observation other than
the baseline measure. The symptom outcomes is measured by biomarkers using MDS-UPDRS
that has five levels to describe various motor impairment domains of PD symptomatology (e.g.,
bradykinesai, dystonia, tremor, rigidity). A PD diagnosis is usually made by a trained neurologist
assessing symptoms in the UPDRS. Since the most severe level has very few observations, we
combine this with the moderate level to get four outcome levels where ”1” indicating normal and
”4” indicating moderate or severe in the data application. Our data set contains a total of 59 items
from the first three parts of MDS-UPDRS.
Our main goals of the analysis include to investigate the impairment patterns among UPDRS
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items, to determine what items occur early in the disease course (e.g., an early inflection point),
and which ones are the most sensitive to increases of age (e.g., a large bk). In addition, we compare
the impairment patterns between two genetic cohorts where one cohort constitutes carriers of a
known genetic risk factor of PD.
To determine which items among all 59 measures should be modelled jointly, we apply a
complete-linkage hierarchical clustering technique using polychoric correlation as the distance.
This step categorizes the 59 biomarkers into 5 groups. We assume that the items in the same group
are likely to share similar parameters for the latent scores Wi, e.g., the same θ and δ. We fit 5 joint
models each for a group of items with gender and standardized baseline age as the baseline covari-
ates. In this section, we will first show descriptive figures of some informative and non-informative
markers, and mainly focus on the analyses of the most informative group consisting of 9 markers.
Based on these 9 informative markers, we will report the results of parameter estimation, predic-
tion of the last observation for each individual, and compare the parameter estimates of the two
cohorts that have different LRRK2 mutations.
2.4.1 Informative vs. Noninformative Markers
To quantify the amount of information for each marker, we apply a method similar to calculating
the item information in the IRT (Partchev, 2004). The information with respect to measuring
subject-specific latent scores can be computed as the Fisher information of Wi given the estimated
parameters. This quantity summarizes the information of an item in terms of discriminant ability in
the population. We plot the information curves in Figure 2.5 for the three representative markers.
Postural Stability (NP3PSTBL) is most informative in measuring subjects with Wi between −2.5
to 0.13. Global Spontaneity of Movement (NP3RTALL) is less informative than postural stability
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for these subjects, but it is more informative if the subjects have Wi less than −2.5. In fact, it is
consistent with the observation in Figure 2.4 where Postural Stability is very informative during
age of 60 to 80 while Global Spontaneity of Movement (NP3RTALL) is moderately informative
for a larger range of age.
To visualize observed data, we present three markers that represent typical markers with dif-
ferent degree of information. In Figure 2.3, all measurements of PD patients from the PPMI study
are categorized into 13 age groups and each line represents the observed proportion of subjects
for each of the 4 outcome levels by age groups. From this figure, we see that Postural Stability
is an informative symptom marker because as age increases, fewer patients will have normal out-
comes (i.e., Y = 1) and more patients will have moderate or severe outcomes (i.e, Y = 4), which
is consistent with the information curve calculated in Figure 2.5, Therefore, Postural Stability is
expected to reflect changes in disease severity and progression. On the contrary, Rest Tremor
Amplitude is a marker with little information since the observed proportion of patients for each
outcome level remains the same as time progresses, except for the 85 − 90 age category which
has a very small sample size. We can detect small changes in observed proportions for Global
Spontaneity of Movement, which represents a moderately informative marker.
Figure 2.4 shows the cumulative probability with respect to age for the three markers using
their estimated parameters. For the ease of interpretation, this figure is presented for patients in
the reference population of males with the mean baseline age. According to the proposed mixture
model, although all patients susceptible to impairment in a symptom domain will eventually ex-
acerbate to the moderate or severe level, there may be a subgroup of patients who are resilient to
impairment on a specific symptom domain measured by a marker over their life time (i.e., Qik = 1
for the kth marker). As a result, the cumulative probability curves may not decrease to 0 for some
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Figure 2.3: Observed proportion of subjects for each outcome level by age groups in the PPMI.
Figure 2.4: Cumulative probability curves from the estimated models for the reference population.
Figure 2.5: Information curves with respect to measuring subject-specific latent scores Wi
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markers (e.g., NP3PSTBL). The inflection point on the curve represents the age when the proba-
bility of a patient having a more severe outcome level increases the most rapidly. In Figure 2.4,
we see that NP3PSTBL degenerates very fast during age of 65 to 80 while NP3BRADY has a
longer and earlier course of progression and can start as early as around 50 years old. Consistent
with Figure 2.3, the cumulative probability curves barely change as age increases for NP3RTALL
because it is not informative.
2.4.2 Analysis Results
We fit a joint model for each of the 5 groups generated from the hierarchical clustering. There
are 200 bootstrap replicates generated to obtain bootstrap standard error (s.e) and 95% confidence
intervals (95% CI). Table 2.2 reports the results for the informative group consisting of 9 markers.
Some markers (e.g., NP3FACXP) have relatively large s.e for η because when η1 is estimated to
have a small negative value, its Fisher information will be intrinsically small, leading to a large
standard error. Except for that, the bootstrap standard errors are overall small, indicating that the
estimates are fairly stable. Recall the observations in Figure 2.4, NP3PSTBL has a more rapid
progression rate and later inflection points due to a smaller value of bk and a larger value of µk than
NP3BRADY.
In another set of analyses, we use the fitted model to predict patients’ symptoms at a future
visit given their previous observations. To this end, we predict the last observation of every patient
in the PPMI applying our joint model to the previous observations from the 9 informative markers.
We obtain the predicted values following the same procedures described in Section 2.3.1.2. Results
are evaluated using prediction accuracy, MAE and RMSE. Figure 2.6 shows the box plots of these









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(red) fitted in the same way described in Section 2.3.1.2. We see that using our proposed model,
all the 9 markers have smaller median values of MAE and RMSE and most of them also have
higher proportions of correctly predicted outcomes. This demonstates that our proposed model
has a better prediction accuracy than a multivariate GLMM model. There are several reasons why
our proposed model performs better than a multivariate GLMM. First, our model incorporates a
mixture component to account for the fact that some patients are resilient to marker symptoms and
always present normal symptoms. A multivariate GLMM directly models on the outcomes with
over-inflated normal symptoms and thus lose some power to focus on the susceptible patients. In
addition, jointly modeling a large number of outcomes using GLMM usually encounters computa-
tional challenges and convergence issues from optimizations of nonlinear multivariate variables.
Lastly, we use our method to characterize disease course for the two genetic cohorts in PPMI.
Although PD has not yet been considered as a genetic disorder, there are a few causal genes predis-
posing PD identified in the past decades (Di Fonzo et al., 2005; Clark et al., 2006). Evidence shows
that leucine-rich repeat kinase 2 (LRRK2) is a known genetic contributor (Di Fonzo et al., 2005)
which significantly increases age-specific risk of PD (Marder et al., 2015). Furthermore, it is of
great interest to compare clinical symptomatology of the genetic forms of PD with idiopathic PD
(Saunders-Pullman et al., 2018). Thus, we sought to investigate whether LRRK2 G2019S carriers
will have a different disease progression rate compared with non-carriers, which can be examined
by comparing parameters µk and bk among carriers and non-carriers. In the PPMI data, there are
331 PD patients with LRRK2 G2019S mutation information, among whom 244 are carriers and 87
are non-carriers. We fit two joint models for the carrier and non-carrier cohort separately using the
9 informative markers. In Figure 2.7, the estimated cumulative probability curves for the reference
population (i.e., males with the mean baseline age) are shown comparing the LRRK2 G2019S
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Figure 2.6: Box plots of prediction metrics comparing our proposed joint model (blue boxes) with
the multivariate GLMM model (red boxes) for predicting the last observation for each of the 9
markers obtained from the 100 bootstrap replicates of the PPMI data set. The prediction perfor-
mance is measured in terms of the proportion of corrected predicted observations (Accuracy), the
mean absolute difference (MAE) and square root of the mean squared difference (MSE) between
the predicted and the true outcomes. The central rectangle box spans the first quartile to the third
quartile with the band inside the box showing the median. The two ends of the whiskers show the
2.5% and 97.5% quantile values. Labels for the markers are: NP2FREZ, Freezing; NP3RISNG,
Arising from Chair; NP3GAIT, Gait; NP3FRZGT, Freezing of Gait; NP3PSTBL, Postural Sta-
bility; NP3POSTR, Posture; NP3SPCH, Speech; NP3FACXP, Facial Expression; NP3BRADY,
Global Spontaneity of Movement.
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carriers (first row) with non-carriers (second row). From the figure we see that for carriers all the
9 markers have longer course of progression, indicating that the disease course span is longer for
the carriers. The carriers starts to experience impairment in many domains (e.g., freezing, gait,
speech) at an earlier age then non-carriers. It is interesting to observe that mild impairment in
cognitive domain (speech, facial expression) occurs earlier than motor domain in both carriers
and non-carriers. In addition, LRRK2 G2019S carriers have slower rates of progression for the 9
markers since values of bk among them are smaller compared with non-carriers. This is consistent
with a prior clinical study (Saunders-Pullman et al., 2018). Table A.1 in Appendix A.2 shows the
specific estimated values for the progression rate (bk) and inflection points at the three levels (µk,
µk − δ2/bk, and µk − δ3/bk) for the 9 markers in the two genetic cohorts. We observe from the
table that for speech, the carriers on average has an inflection point of the cumulative probability
curve for P (Y ≤ 3) (blue) 23 years later than the noncarriers.
2.5 Discussion
In this work, we propose a nonlinear mixture model with subject-specific random inflection points
to jointly fit ordinal markers in longitudinal data. At population level, our model can estimate
marker-specific disease progression rates and inflection points of trajectories in order to under-
stand the time-dependent ordering of markers and identify the informative ones for assisting di-
agnosis. In addition, we can investigate the effect of personal characteristics on the trajectories
through subject-specific inflection points and a susceptibility indicator. We use ACL to model
clinical signs of the susceptible patient group. Compared with the cumulative logit model un-
der the proportional odds assumption, the ACL model has a simple linear form for log-likelihood
function, which helps accelerate the optimization process. However, our conceptual framework of
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Figure 2.7: Cumulative probability curves from the estimated models for the reference population
comparing the LRRK2 G2019S carriers cohort (first row) with the non-carriers cohort (second
row) in the PPMI study. Labels for the markers are: NP2FREZ, Freezing; NP3RISNG, Aris-
ing from Chair; NP3GAIT, Gait; NP3FRZGT, Freezing of Gait; NP3PSTBL, Postural Stability;
NP3POSTR, Posture; NP3SPCH, Speech; NP3FACXP, Facial Expression; NP3BRADY, Global
Spontaneity of Movement.
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mixture modeling can be extended to proportional odds model without difficulty. An efficient EM
algorithm is implemented with explicit solutions derived in each step for this nonlinear mixture
model.
From our analysis of the PPMI data set, we found that items Facial expression (NP3FACXP)
and Global spontaneity of movement (NP3BRADY) occur early in the disease course and can
be used as indicators of early disease signs; Postural stability (NP3PSTBL) and Freezing of gait
(NP3FRZGT) are most sensitive to the change of age and thus are useful for monitoring disease
progression. Our results of comparing genetic PD with idiopathic PD are also consistent with an
earlier study (Saunders-Pullman et al., 2018) that LRRK2 carriers have a slower PD progression
rate and longer disease course span than non-carriers as measured by the 9 MDS-UPDRS markers
in Section 2.4.
Several extensions can be considered in the future work. First, our model assumes that a
subject has a single latent score shared across markers. In practice, however, each patient can be
represented by more than one latent scores for different groups of biomarkers. While multivariate
latent scores allow such flexibility, the main obstacle lies in the presence of higher dimension
of irreducible integrals. Approximated inference including expectation propagation or variational
Bayes maybe be considered. Moreover, advanced models are required to improve prediction for
outcomes of future patients. For example, due to heterogeneity of patients and markers, jointly
partition markers and subjects without the initial step of hierarchical clustering may be desirable.
Lastly, we can consider extending our model on discrete outcomes by integrating it with continuous
models (Sun and Wang, 2018) to make use of information from various sources. Some of these
extensions are discussed in Chapter 3.
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Chapter 3
Multi-layer Exponential Family Factor Models for Learning Mechanisms of
Disease Progression
3.1 Introduction
Patients affected by neuropsychiatric diseases often exhibit substantial heterogeneity in disease
progression measured by cognitive, behavioral and biological measures. Due to a lack of gold stan-
dard biomarkers, diagnosis of neurological disorders (e.g., Parkinson’s disease, PD; Alzheimer’s
disease, AD) still heavily relies on clinical symptoms that occur at a late disease stage. Recent
research has shown that disease-related biomarkers and subtle cognitive signs may follow a tem-
poral ordering with varying rates of deterioration as the disease progresses. For example, Jack Jr
et al. (2010) suggested that certain cerebrospinal fluid (CSF) biomarkers decline much earlier than
neuronal dysfunction and cognitive symptoms (e.g., memory loss) for AD. Thus, it is important
to identify markers that can measure the earlier pathological changes associated with underlying
disease progression. In addition, since no gold standard diagnostic criteria defined by an objective
biological marker is available for neurological disorders, it is also of interest to simultaneously
integrate multiple data modalities (e.g., biological markers, cognitive or psychiatric signs, motor
symptoms) to measure disease progression.
Analysis of data collected in a single domain does not allow for a comprehensive character-
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ization of disease risk and progression. Although evidence has started to emerge from separate
studies of genetic variants and neuroimaging biomarkers associated with PD, only a handful have
been replicated, and some are contradictory (Chen-Plotkin, 2014). There is a growing body of lit-
erature suggesting that it is beneficial to examine the complementary contribution from genomic,
imaging and CSF biomarkers to study susceptibility or risk of neurological disorders. Given the
multiple genetic causes for complex diseases (e.g., PD and AD), the variability of markers and
the evident heterogeneity of symptoms across subjects (Wang et al., 2013), it is likely that multiple
markers with utilities ranging from molecular genetic mechanisms (e.g., causal mutations), disease
pathological states (e.g., spinal fluid biomarkers or neuroimaging measures) to clinical symptoms
need to be integrated to fully map disease risk and progression (Chen-Plotkin, 2014).
Integrating multi-domain disease markers and clinical data offers a comprehensive modeling
of complex diseases resulting from an elaborate interplay among biological factors, environmental
exposures and behavioral or lifestyle factors. However, several challenges hamper the integration
of heterogeneous types of longitudinal markers to model neurological disease progression. First,
current research suggests that the progression profiles of many clinical and biological markers are
nonlinear (Jack Jr et al., 2010), and jointly modeling multivariate nonlinear random variables often
lead to computational instability. Furthermore, the clinical symptoms and markers are measured
on different scales, and not all of them are collected for all subjects. In addition, patients enter
a study at different stages of the disease and are usually followed within short time periods. As
a result, the measurements are not aligned to directly observe the long-term disease pathological
processes.
Despite the evidence of nonlinear disease progression, mixed models assuming linear progres-
sion are often used in clinical applications to model patients with repeated measures and allow
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subject-specific random variation, partially due to a lack of appropriate methods and stable soft-
ware implementation for nonlinear models. For example, Lessig et al. (2012) investigated the
change of two cognitive instruments, Mini–Mental Status Examination (MMSE) and Montreal
Cognitive Assessment (MoCA) among PD patients over time using a linear mixed effects model
(LME). Kennedy et al. (2015) used MMSE as a covariate in LME and estimated the rate of cogni-
tive decline using Alzheimer’s disease Assessment Scale-cognitive (ADAS-Cog) scores. Further-
more, most existing studies focus on modeling a single outcome using LME or generalized linear
mixed models (GLMM). In fact, when jointly modeling a large number of discrete outcomes,
GLMM often terminate with failure of convergence due to complex random effects structures.
With increasing computational power and Bayesian estimation techniques (e.g., Markov Chain
Monte Carlo [MCMC]), some multivariate models have been proposed to accommodate interac-
tions among multiple outcomes. For example, Iddi et al. (2018) extended the multivariate LME
using a latent time joint mixed effects model, but this method only applies to continuous outcomes
with an identity link function, and the computation is intensive for large-scale data. Simultaneously
modeling a large number of measures with different types of distribution remains a challenge.
In this work, we propose a generative model to integrate a large number of markers from
different modalities and mixed data types (e.g., continuous and ordinal) to simultaneously learn
their interactions and effects on disease progression. Our model is based on composing distribu-
tions from the exponential families with latent variables in a hierarchical fashion. We simulta-
neously examine the associations among these markers in the latent space so as to create lower-
dimensional factors and partition patients into biologically meaningful, homogeneous subgroups
based on shared variation across data modalities. There are three main foci of our approach on
modeling disease progression: (1) The model will allow the markers’ distribution types to be het-
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erogeneous and use corresponding exponential family for each type; (2) We will use a generative
hierarchical model with nonlinear trajectories to capture associations between markers and iden-
tify the order of impairments by examining model parameters (e.g., average inflection points); (3)
We allow subject-specific random inflection points to accommodate patients’ differential stage of
disease and align them in the latent space; (4) To accommodate between-patient heterogeneity,
the model will produce modality-specific factor scores and shared factor scores across modalities
that can distinguish patient subgroups in terms of their disease progression stages based on both
clinical symptoms and shared variation with biomarkers. Abnormal patients severely impaired in
a domain can be detected based on their distributions in the latent space so that the model can be
used for normative modeling (Marquand et al., 2016).
Our modeling framework is based on a Multi-layer Exponential Family Factor (MEFF) model
with nonlinear trajectories over time consistent with theories of disease cascade and evidence in
empirical studies (Jack Jr et al., 2010). The convergence of algorithms for fitting such nonlinear
latent models with large-scale, mixed type outcomes is a challenging statistical problem. For a sin-
gle outcome, the computation and estimation of nonlinear mixed effects models often use various
approximations of the log-likelihood function (Pinheiro and Bates, 1995), including Laplacian ap-
proximation (Wolfinger, 1993), linear mixed effects model approximation (Lindstrom and Bates,
1990), Gaussian quadrature (Davidian and Gallant, 1992), or penalized quasi-likelihood (Bres-
low and Clayton, 1993). However, these methods become unstable or infeasible when models are
highly nonlinear and outcomes are multivariate consisting of different types (e.g., continuous and
discrete). There are three main numeric challenges for fitting large-scale nonlinear models. They
arise from the computation of integrals over the multi-dimensional latent factors, the optimization
of the nonlinear objective function, and the dependence of the model optimization used for each
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data type. To overcome these challenges, we propose to fit the model with state-of-the-art compu-
tational techniques for large-scale data based on variational inference (VI) (Jordan et al., 1999; Blei
et al., 2017). The optimization method is sufficiently general to accommodate multiple distribu-
tions in the exponential family and connect latent variables and observed variables in a hierarchical
fashion. To accommodate a large number of markers and observations, stochastic gradient descent
is used for optimization (Ranganath et al., 2014). Therefore, the method is applicable to “wide
and tall” large-scale data with repeated measurements not necessarily aligned among subjects. We
show feasibility of the method through simulation studies and an application to clinical symptoms
and biomarkers collected in the Parkinson’s Progression Markers Initiative (PPMI) to model the
progression of PD.
3.2 Construction of the Generative Models
3.2.1 Integration of Different Data Modalities
Let Y (m)ijk denote measurement of the kth time-varying marker within the mth data modality at visit
j on the ith subject, let Xik denote time-invariant covariates to be adjusted for confounding (e.g.,
demographics) or to inform disease mechanisms (e.g., genetic mutation), and let tijk denote the
observed measurement time or age. Different modalities of outcomes (e.g., clinical symptoms,
CSF biomarkers, neuroimaging biomarkers) can be of different data types (e.g., continuous, ordi-
nal, discrete), and each type requires a different link function under the exponential family models.
Assume that the first modality Y (1)ijk measures ordinal clinical markers (e.g., items in an instrument
measuring severity of motor symptoms for PD patients), where Y (1)ijk = 0 indicates normal symp-
toms with larger integer values indicating more severe impairments. A commonly used model from
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measurement theory in psychology and psychiatry is the item response theory (IRT) model, where
dichotomous markers are modeled using logit link functions incorporating latent traits (Partchev,
2004). Our model for ordinal markers is based on an extension of the IRT, which accommodates
inflated normal symptoms for long-term resilient subjects using a Bernoulli random variable Qik.
A subject with Qik = 1 is not susceptible to pathological changes manifested through the kth
marker and therefore will always have normal symptoms during the life course (i.e., Yijk ≡ 0 for
all j = 1, ..., nik). On the contrary, susceptible patients will have ordinal outcomes Hijk following
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 ∼ N(0, I). (3.2)
In (3.1), the outcome follows a zero-inflated adjacency category model given the unobserved
random variables W (1)ik . Parameters (bk1, µk1,ηk1,θk1, δck) are global parameters specific to a
marker’s trajectory shared by all subjects. The parameter bk1 indicates the marker-specific rate
of impairment. Since the probability of having less severe symptoms decreases as age tijk in-
creases, bk is constrained to be negative. Parameter δck allows the inflection point age to differ for
different successive outcome levels. The random subject-specific inflection point d(1)ik indicates the
age that a susceptible patient with an outcome level c will have to pass in order to have a higher
chance to reach level c + 1 of the k marker. It is also the age when the impairment probability
curve P (H(1)ijk ≤ c|W
(1)
ik ) decreases the fastest with respect to tijk. W
(1)
ik are local latent variables
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allowing individual shifts around a group-average mean age of inflection point, µk + θTk1Zi. These
random shifts allow patients to be at different stage of their disease progression when entering the
study, and the progression trajectory is governed by global parameters.
The subject- and marker-specific inflection point age dik is a critical landmark point, since it
represents the time when the deterioration from a normal state occurs at the maximal rate. The
values of dik indicate the temporal ordering of the K markers as the disease progresses for the
ith subject. It is further modeled as a linear function of fixed covariates Zi and the zero-mean
random shift scores W (1)ik . In (3.2), an inter-battery latent factor model (IBFA) is used to capture
subject-specific disease progression measured by multiple markers jointly. The factor model in
(3.2) expresses variations among observed markers through a lower-dimensional, oriented sub-
space spanned by modality-specific latent factors u(m)i (m = 1 for the first modality) and common
latent factors u(s)i shared across all modalities. Loadings Am and Bm specify relative contributions
of common and modality-specific latent factors to the latent space. Details are described in Section
3.2.2.
In addition to discrete clinical markers, important continuous measures from biological, cog-
nitive and imaging data modalities are often collected. To accommodate nonlinear disease pro-
gression measured by CSF or imaging biomarkers, Sun and Wang (2018) transferred modeling
sigmoidal nonlinear trajectories into modeling probabilities of Bernoulli latent variables so that
the marginal distribution of biomarker would be sigmoidal. This model is within the class of latent
nonlinear mixed effects model with random inflection points, which is difficult to fit as reviewed
in Section 1. However, by formulating a nonlinear model as a mixture of two latent states (e.g.,
Q,H), each with a linear trajectory, but with switching probability depending on time through
a nonlinear link function, a linearization of nonlinear model is achieved. This linearization re-
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duces some parameter optimization to weighted least squares regressions, and thus circumvents
unreliable computation. The previous work in Sun and Wang (2018) neither performs integrative
analysis of multi-modality measures nor dimension-reduction, which are the foci of the current
work.
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 ∼ N(0, I). (3.4)
The scale parameter ak is constrained to be positive and represents the magnitude of change in-
duced from the two states. Here, we define Y (2)ijk in a way such that smaller values indicate more
severe impairments, which is often the case for cognitive markers. The linear terms β>0kXi and
β1ktijk account for impairments due to normal aging. Thus, we should expect β1k to be negative as
aging will impair the cognitive functions. The parameter bk2, the variables Qik and d
(2)
ik are mod-
eled similar as in model (3.1), and εijk ∼ N(0, σ2ε ) are normally distributed measurement errors.
One difference in (3.3) is that H(2)ijk is a binary variable with one indicating a mild disease state and
zero for a severe state. As a result, when a patient has long-term resilience (i.e., Qik = 1), or when
a patient has a mild disease state (i.e., Hijk = 1) for the kth marker, we should expect to see a less
impaired outcome with ak added.
This model combines the linear trend and the well known sigmoidal trajectories at population
level when marginalize Q(2)ik and H
(2)





allows modeling the probability of switching between a mild and a severe status. The factor model
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for W (2)ik in d
(2)
ik serves a similar role as in (3.2). The latent factors u
(2)
i are used to capture un-
derlying subject-specific properties uniquely manifested by continuous markers specifically to the
second modality.
A graphical illustration of the MEFF model for each patient i can be found in Figure 3.1. In
our MEFF, u(s)i reflects the disease progression of a patient and can be used to investigate the
underlying subgroups of patients (e.g., by performing a clustering analysis of u(s)i or model them
as a mixture Gaussian distribution).
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Use mixture of exponential family 
distributions in model (2.1)-(2.4)
Figure 3.1: An example of the generative model of MEFF with two data modalities for the patient
i. The stacked outcomes represent records of multiple visits for a patient and a marker. The obser-
vations space is represented by the lower-dimensional latent factor u(s)i shared across modalities
and the unique latent factor u(m)i specific for each modality m. u
(s)
i is informative to reflect the
underlying disease progression of subjects from different subgroups.
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3.2.2 Inter-battery Factor Model for the Latent Space
IBFA (Tucker, 1958) has recently been re-interpreted from a probabilistic perspective (Browne,
1979). It has a close connection with probabilistic canonical correlation analysis that aims to
obtain components for capturing correlations between two sets of random variables (Bach and
Jordan, 2005). In contrast, IBFA models not only provide a latent lower-dimensional subspace
shared among all the modalities, but also include modality-specific latent variables to account for
each data modality’s unique variability. The main idea of IBFA has been extended to exponential
family to demonstrate its capability to separate shared information from those specific to each
modality (Klami et al., 2012).
Different from current literature that applies IBFA directly to observed outcomes, we use it to
factorize the random shift scores W(m)i embedded in (3.2) and (3.4). In the case of two modalities,

































Ls+L1+L2 , and u(s)i ∼ N(0Ls , ILs), u
(m)
i ∼
N(0Lm , ILm) for m = 1, 2. Here, we have decomposed the lower dimensional latent space into





Note that the dimension of ui, Ls + L1 + L2, is assumed to be much lower than the number of
markers K1 + K2. Thus the IBFA model also serves the purpose of dimension reduction. The
group-wise sparsity structure imposed for the loading matrix Λ in (3.5) helps to resolve the issue
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of unidentifiability regarding to allocating the shared and unique components (Klami et al., 2013).
This model has the advantage of capturing the common variation and learning robust information
using all data domains. In particular, when predicting one data source Y(1)i from the other source
Y
(2)
i , not all variation of Y
(2)
i is relevant. Using only denoised, and shared latent factors to predict
one from another is sufficient, which is similar to the rationale of a partial least squares analysis.
In our model, the shared latent factors u(s)i are used to reflect the underlying subject-specific dis-
ease progression status combining observations from all modalities. Hence the fitted shared latent
factors based on posterior distributions given observed data can provide comprehensive and robust
information to distinguish patients in heterogeneous subgroups.
Several features of our modeling framework are worth noting. First, the model maintains non-
linear trajectories observed for markers in neurological disorders. To compare marker trajectories
between patient subgroups and predict personalized trajectories, the model incorporates subject co-
variates (Xi) informative of disease progression (e.g., mutation status, baseline levodopa treatment
status) and subject-specific latent factors (ui). Second, instead of assessing individual markers
separately, we jointly estimate a large number of markers to borrow information and reduce dimen-
sionality using latent factors. The overlaps of variance among markers are effectively accounted
for by the shared latent factors. Third, we can compare and establish temporal relationships across
markers by estimating marker-specific parameters (e.g., bk and µk) and mapping different types of
markers onto the same latent space so that they are comparable. In conclusion, MEFF recognizes
and organizes disease markers to jointly model the underlying long-term disease course as well as
learn shared information across multiple domains and unique information specific to a domain.
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3.3 Estimation and Inference
Denoting Ψ as all the parameters in the model, the marginal log-likelihood is













With observed data (Y (m)ijk ,Xi, tijk) and the latent variables u, the goal is to learn the global pro-
gression parameters for each modality (e.g., bkm,ηkm, µkm,θkm, etc.), along with K × L factor
loadings Λ. For estimation in latent variable models, EM algorithm is widely used. However, due
to intractability of posterior expectation of multiple layers of latent variables and nonlinearity in
our model, it is impractical to use EM algorithm especially for large data sets with many mark-
ers. In these settings, variational inference (VI) provides an approximation with an easy method to
assess convergence through optimizing a variational lower bound (Blei et al., 2017). Specifically,
VI requires to propose a variational distribution q(u;ν) parameterized by ν to obtain adequate
approximation of the conditional distribution of latent variables given observed data (i.e., p(u|y))
(Jordan et al., 1999; Bishop, 2006; Wainwright et al., 2008). This is equivalent to maximize the







du ≤ log p(y).
Based on the form of the likelihood in model (3.1), when using the logit link for Qik and Hijk, the
posterior p(u|y) is intractable. However, VI overcomes this hurdle by avoiding numeric integration
over multivariate latent factors ui, and thus substantially speeding up computation.
Black box variational inference (BBVI) was proposed for VI to be easily applied and imple-
mented for a wide variety of models (Ranganath et al., 2014). BBVI replaces tedious model-
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specific derivations of gradients in the updates of VI by an equivalent form and leverages com-
putational power, which forms the cornerstone of deep exponential family (Tran et al., 2017). It
derives a noisy but unbiased estimator for the gradient of evidence lower bound (ELBO) of the the




log p(y,u)− log q(u;ν)
)]
. With variational
distribution q of any proposed easy form, we can numerically compute the gradient by drawing
Monte Carlo samples. Then stochastic optimization can be used to maximize L(ν) and easily
scale to large number of observations. One advantage of BBVI is that the computation of the
gradient ∇ν log q(u;ν) does not involve the underlying model. Therefore, as long as the model-
specific complete data log-likelihood and the proposed variational distributions can be numercially
evaluated, any probabilistic programming package can be applied to automatically estimate an ap-
proximate for the posterior distribution. Therefore, the optimization challenges of fitting nonlinear
models are tackled by stochastic sampling and using generic model-independent gradients, which
is scalable to big data (Tran et al., 2016, 2017). Edward is such a Python library built on Ten-
sorflow to support probabilistic modeling, efficient inference and techniques for model criticism
(Tran et al., 2016, 2017). In this work, Edward is used for model estimation and inference.
3.4 Simulation Studies
We conducted a simulation study to examine the performance of the proposed method by simu-
lating data that closely reflects the observed PPMI study data. There were N = 1, 000 simulated
subjects with ages from 30 to 90 who shared the same baseline covariates (i.e., gender) as the PPMI
study cohorts. For the ease of presentation, we considered only two domains with the first modality
Y
(1)
ijk simulated from 6 ordinal outcomes taking integer values from 0 to 3, and the second modality
Y
(2)
ijk simulated from 4 continuous outcomes. Each subject has on average 9 repeated visits in the
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spectively, and a shared 2-dimensional latent factor u(s)i that correlates the two modalities. The
parameters were estimated using BBVI implemented in Edward 1.3.5. Due to the local optimum
issue of variational inference, we run the algorithm with multiple different sets of initial values and
chose the estimates with the largest variational lower bound for each data set.
We report the estimates of the important parameters directly related to describing the disease
progression (i.e., b,µ,η,θ, δ,β,a) in Table 3.1 from 100 simulated data sets. We see that all the
mean estimates have small biases from the true parameter values (highlighted in bold) with small
standard deviations. In particular, b for maker-specific rate of impairment and µ for population-
level inflection point age are two crucial parameters to distinguish useful markers and perform
temporal ordering. Both of the two parameters are precisely estimated for all the makers. In
conclusion, the proposed MEFF can be estimated accurately using BBVI.
3.5 Applications to the PPMI Study
3.5.1 Study Design
The PPMI is a large international study of PD that aims to identify biomarkers of PD progression
using longitudinal multi-modality data including clinical measurements, and biological markers
including genetics and neuroimaging measures (Marek et al., 2011). To understand the disease pro-
gression and distinguish markers of early PD patients from other signs, the PPMI study recruited
8 cohorts with different genetic backgrounds and different disease diagnostic statuses determined
at baseline by trained neurologists. Four major cohorts include de novo “PD” cohort (early PD
44
Table 3.1: The parameter estimates of the 100 simulated data from two modalities mimicking PPMI.
m = 1 (Ordinal) m = 2 (Continuous)
k = 1 k = 2 k = 3 k = 4 k = 5 k = 6 k = 1 k = 2 k = 3 k = 4
b1 -4.0 -0.5 -2.0 -0.5 -1.0 -1.5 b2 -4.5 -6.0 -4.5 -4.5
Bias∗ -0.023 -0.062 -0.042 -0.004 -0.019 -0.015 -0.001 0.002 0.001 -0.000
s.d 0.133 0.062 0.067 0.048 0.062 0.082 0.012 0.017 0.015 0.019
µ1 2.0 0.5 1.5 1.5 1.0 1.0 µ2 1.5 1.0 1.0 0.5
Bias -0.063 0.046 -0.079 0.076 0.021 0.042 -0.035 -0.032 -0.010 -0.006
s.d 0.041 0.091 0.064 0.145 0.064 0.061 0.051 0.069 0.012 0.013
η10 -3.0 -5.5 -3.5 -4.0 -5.0 -3.0 η20 -6.0 -4.5 -5.5 -5.0
Bias 0.009 0.362 -0.032 0.012 0.697 -0.061 0.233 -0.372 -0.81 -1.176
s.d 0.295 0.423 0.275 0.531 0.612 0.369 0.362 0.275 0.493 0.561
η11 0.5 1.0 0.0 0.0 2.5 -0.5 η21 0.0 0.8 0.5 0.2
Bias -0.012 -0.372 0.035 -0.301 -0.710 0.008 -0.048 0.241 0.312 -0.37
s.d 0.313 0.535 0.294 0.854 0.669 0.441 0.263 0.19 0.389 0.907
θ1 0.0 -0.5 0.0 0.5 0.5 0.0 θ2 0.5 0.0 0.2 0.8
Bias -0.074 -0.477 -0.111 -0.135 -0.094 -0.094 0.008 -0.013 -0.001 -0.009
s.d 0.057 0.463 0.094 0.152 0.099 0.080 0.080 0.105 0.018 0.020
δ1 0.5 4.0 1.5 0.5 2.0 2.5 β1 -0.5 -1.0 -0.5 -0.5
Bias 0.025 0.096 -0.008 -0.003 0.043 0.010 0.000 0.001 0.008 0.016
s.d 0.107 0.091 0.072 0.057 0.077 0.075 0.006 0.006 0.020 0.011
δ2 3.5 6.0 1.5 0.5 1.5 3.0 a 8.0 8.5 6.0 5.0
Bias 0.036 0.263 0.051 -0.002 0.044 0.008 0.006 -0.024 -0.002 -0.010
s.d 0.155 0.137 0.089 0.068 0.103 0.115 0.011 0.016 0.020 0.018
∗ The bias is calculated from the mean bias from the truth. The true parameter values are in bold.
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patients), “HC” cohort (healthy controls) and “Prodromal” cohort (non-diagnosed PD with early
non-motor symptoms). There is a high chance for a prodromal patient to be diagnosed with PD
in the near future. Therefore, it is crucial to distinguish prodromal cohort from health controls in
order to develop effective early interventions before severe symptoms appear. Although prodromal
patients had complete information on several cognitive measures (e.g., delayed recall, Figure 3.2),
most did not have data from imaging biomarkers (e.g., caudate and putamen). Hence, it would be
beneficial to borrow information from other similar subjects to study the PD progression for pro-
dromal subjects. The other patient cohorts include “SWEDD” cohort (patients without dopamine
deficits in the DaTscan imaging), “GCPD” cohort (patients with genetic mutation in LRRK2, GBA,
or SNCA) and “GRPD” cohort (patients of genetic registry). Similarly, the other control cohorts
include “GCUN” and “GRUN” cohort.
A complication for multi-modality analysis of the PPMI is that not all the subjects have com-
plete outcome measurements for all the markers, which is a challenge that often occurs in practice
for joint models. More specifically, PPMI study cohorts were assessed under different schedules.
In the study period, 19% of the subjects have only baseline measurements and, 52% have 7 to 15
repeated measures. The median length of follow-up time is four years among those who have at
least one observation other than the baseline measure. The advantage of MEFF is that it can allow
such missingness and still produce the shared latent factor scores u(s)i for a subject by borrowing
information from the subject’s other available outcomes and from other similar subjects. Figure 3.2
shows that the missingness patterns of the PPMI study are quite different across cohorts: 43.25%
subjects of the genetic cohorts do not have data on MDS-UPDRS, and 64% of prodromal patients
have no records on both MDS-UPDRS and SCOPA-AUT items. In this case, methods such as





Figure 3.2: Heat map of subject-and-marker-specific observed symptom scores by taking the av-
erage across repeated measures of a subject (columns for subjects and rows for markers). Red
color indicates more severe symptoms and blue color indicates mild symptoms. Missing records
are in gray. The columns are arranged in eight cohorts according to subject diagnostic status at
baseline. GRPD and GRUN cohorts miss much of autonomic measures. Prodromal cohort has
sparse measurements of many markers.
47
We will tackle these challenges using MEFF.
To incorporate information from different sources, we considered 10 modalities, including clin-
ical, cognitive, imaging and biological markers. The first modality contains categorical measures
from MDS-UPDRS, the most common scale used to measure PD severity in terms of non-motor
autonomic functions and motor symptoms. Each item has five levels to describe various impair-
ment domains of PD symptomatology (e.g., bradykinesia, dystonia, tremor, rigidity). Because the
most severe level has very few observations, we combine it with the moderate level. Since some
items have the same score for most of the subjects, we only focus on the 30 items with some vari-
ability in the analysis. The second modality contains 21 categorical SCOPA-AUT items measuring
autonomic functions that are important for early PD. In addition, we have 6 continuous modal-
ities of cognitive measurements. They include semantic fluency test (VLT), Montreal cognitive
assessment (MoCA) (i.e., MCATOT, visuospatial, attention, language, delayed recall, orientation),
symbol-digit modalities (SDM), letter number sequencing test (LNS), Hopkins verbal learning test
(HVLT), and Benton judgment of line orientation (JLO). We also have one modality for CSF bio-
logical markers (i.e., Aβ1−42, α-synuclein, p-tau and t-tau), and one for DaTscan imaging markers
(i.e., caudate and putamen). All markers in the continuous modalities are standardized to mean
zero and variance one for modeling.
We summarize subject-and-marker-specific observed symptom scores by taking the average
across repeated measures of a subject, and visualize the available observed data in Figure 3.2 and
its correlation matrix of all 77 markers in Figure 3.3a. Due to limited space, we only list the names
for half of the markers in both figures. The observed data in Figure 3.2 shows that overall patient
cohorts (i.e., “PD”, “SWEDD”, “GCPD” and “GRPD”) have more severe symptoms across mark-
ers than control cohorts (i.e., “HC”, “Prodromal”, “GCUN” and “GRUN”). Consistent with cohort
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description, “SWEDD” subjects do not have severe symptoms in DaTscan imaging markers (e.g.,
caudate and putamen), and “Prodromal” subjects do not have severe MDS-UPDRS markers (e.g,
NP1SLPN). Figure 3.3a shows that the markers of the same modality or measuring the same types
of symptoms (e.g., cognitive functions) form a cluster with highly correlated markers. Specifically,
we see clusters of MDS-UPDRS markers, cognitive markers (e.g., VLTFRUIT), biological mark-
ers (e.g., t-tau) and imaging markers. As a comparison, the SCOPA-AUT markers (e.g., SCAU1)
have smaller within-group correlations. Data from different clusters can also have between-group
correlations. For example, the DaTscan imaging markers are highly correlated with MDS-UPDRS
Part II items (e.g., NP2SPCH). This is consistent with the fact that current diagnosis of PD heavily
relies on MDS-UPDRS and DaTscan imaging markers.
The visualization results indicate that PPMI measures collected from different modalities de-
scribes the disease progression from distinct perspective while they also share some underlying
common features. We will use MEFF model to: (1) identify both shared and unique latent factors
in lower dimensions of the observed measures across all domains, and use the shared latent factors
to cluster patients into more interpretable homogeneous groups; (2) identify combinations of mark-
ers to better distinguish diagnostic groups (e.g., prodromal patients from PD and HC subjects), and
possibly establish new ways of improved diagnosis.
3.5.2 Fitting MEFF on PPMI
We fit MEFF on PPMI data using 2, 131 subjects from eight diagnostic cohorts measured by 77
markers from 10 modalities. Since gender differences are observed in PD (Shulman, 2007), we
include gender as a covariate in the analysis. Based on prior knowledge and observed correlation
patterns from Figure 3.3a, we assume that the 10 modalities share latent factors u(s)i of dimension
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three and each modality has its own unique latent factor. To achieve identifiability and force the
shared and unique latent factors to represent different information, we constraint all factors to be
uncorrelated with one another. In the VI optimization step, different initial values are explored,
while the algorithm aims to maximize the ELBO function in Section 3.3 to estimate the model
parameters and latent factors. The optimization process takes around 6 to 8 minutes to converge,
which is fast given a large number of observations and markers.
From the fitted model, we obtained all the parameter estimates as well as the posterior means
of u(s)i and u
(m)
i for each modality m given the observed data as the estimates for the latent factors.
To compare observed outcomes versus fitted outcomes, we obtain the correlation matrix from the
observed symptom scores in Figure 3.3a and the correlation matrix using fitted symptom scores
Ŷijk in Figure 3.3b. The fitted scores not only preserve major information from observed data
but also reveal much stronger patterns after removing noises. To examine correlation in the latent
space, let ûi denote all posterior means of latent factors concatenated together. Since the subject-
and-marker-specific random inflection point shifts W are not observed, we first estimate them
using ûi and estimates of Λ as discussed in Section 3.5.2. Figure 3.3c is the heatmap of the
correlation matrix of Ŵ obtained by concatenating Ŵi = Λ̂ûi for all subjects. Compared with the
correlation matrix of the observed symptoms in Figure 3.3a, the estimated inflection point shifts
Ŵ not only capture the similar patterns for both within and between modalities, but also much
enhance the correlation structures after adjusting for age, disease resilience, rate of impairment
and so on. Specifically, SCOPA-AUT items are highly correlated with MDS-UPDRS Part I items,
which is expected because they all measure autonomic functions. In addition, SCOPA-AUT items
are roughly divided into three groups where the first and the third group are highly correlated.
Consistent with findings of the observed data, Figure 3.3b from the fitted model also indicates that
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DaTscan imaging markers have high correlations with motor markers (i.e., MDS-UPDRS Part II
and Part III). On the contrary, most markers from cognitive tests are not directly correlated to the
other modalities.
3.5.3 Latent Factor Representation of PD
The factor loading matrix contains valuable information to describe the representation from the
high-dimensional observation space to the low-dimensional latent factors learned from PPMI. We
first calculate correlation coefficients between estimated random inflection shifts Ŵ and latent
factors û. Note that in the traditional factor analysis when W are observed and standardized, the
factor loadings Λ are the correlation between each latent factors in u and each observed variable
in W. However, since in our analysis W can not be observed and standardized beforehand, we
will calculate the pairwise correlation coefficients between theK fitted marker-specific shift scores
in Ŵ and the L estimated latent factors in û. Figure 3.4a shows the heatmap of the correlation
matrix where each row is a maker and each column is a latent factor. The first three columns are
the 3-dimensional shared latent factors from which we see that the third factor u(s)3 mainly rep-
resents MDS-UPDRS and DaTscan markers. Since PD diagnosis is based on motor symptoms
and dopamine deficit in DaTscan imaging, this latent factor plays the most important role in dis-
tinguishing patients from control groups. For example, from the density plot in Figure 3.4b, we
see that “PD” and “HC” cohorts are well separated using u(s)3 . In addition, “Prodromal” cohort is
another important group of interest because prodromal subjects can hardly be distinguished from
HC based on motor symptoms, but they have a high chance of converting to PD in the later course.
Since u(s)3 contains not only the motor and DaTscan markers but also incorporates other important





















































































































































































































































































































































































































Figure 3.3: Heat map for correlation matrix of the 77 markers averaged across patient repeated
measures. (a) For observed symptom scores. (b) For model fitted symptom scores. (c) For subject-
and-marker-specific fitted shift scores W based on the MEFF. MEFF inferred correlation patterns
(b) greatly enhanced the correlation patterns from observed data (a) by removing noises and re-
vealing hidden patterns. Markers measuring same domain of functions have high correlations.
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as in Figure 3.4b. Therefore, our model shows the potential to improve diagnosis by integrating
information from multiple modalities. The second shared factor u(s)2 is almost solely loaded on
markers from cognitive tests, indicating that the modality measuring cognitive functions does not
interact directly with other modalities. The first latent factor u(s)1 is loaded on SCOPA-AUT items
and MDS-UPDRS Part I items both of which represent autonomic functions. Figure 3.4c shows
the scatter plot of u(s)1 and u
(s)
3 , where we see that “PD”, “HC” and “Prodromal” subjects differ in
the direction of u(s)3 due to different locations and prodromal subjects differ in the direction of u
(s)
1
due to different variances. To summarize, the correlations between predicted W and u provide
an intuitive way to understand the utility of latent factors. Our model has flexible interpretations
while also maintains good power to distinguish subjects with different diagnostic status.
PD patients often present heterogeneous clinical symptoms and disease patterns, making it
challenging for establishing diagnostic criteria and developing effective treatments. Since the
shared latent factors contain major information common to many modalities, they are valuable
for clustering patients into meaningful subgroups based on both clinical symptoms and shared
variation between motor symptoms and biomarkers. We utilize the shared latent factors to clus-
ter the early PD patients into five subgroups using Gaussian mixture modeling. The number of
subgroups is determined by the Bayesian information criterion (BIC). Figure 3.5 shows the scat-
ter plots of the clustered PD cohort patients. Figure 3.5a shows that u(s)3 (representing motor and
DaTscan imaging markers) and u(s)1 (representing autonomic functions) can separate subgroups 3,4
and 5 from the others. Subgroups 1 and 2 have similar motor and autonomic latent factor scores,
but they differ on the dimension of u(s)2 that represents cognitive markers. Since patients in the
same subgroup share similar progression profiles, they can be studied together to reduce patient
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Figure 3.4: (a) Heat map of the correlation between each subject-and-marker-specific fitted shift
scoresWik and each latent factor. (b) Smoothed density plot of the third shared latent factor u
(s)
3 for
cohorts HC, PD and Prodromal. (c) 2-D density map for the two shared latent factors, with colors




Figure 3.5: The scatter plots for clustering PD patients into five subgroups using a Gaussian mix-
ture model (GMM) with three shared latent factors. (a) Scatter plot for u(s)2 vs. u
(s)
3 . (b) Scatter plot
for u(s)1 vs. u
(s)




3 , and PD subgroups 1
and 2 can be separated using u(s)2 .
3.5.4 Validation and Temporal Ordering of Neurodegeneration of PD
To validate the findings from the MEFF models, we use clinically important external variables that
have not been used in the model fitting to demonstrate the validity of the fitted shift scores. One
external marker is the initiation of medication as an important milestone that indicates disease pro-
gression to the next level so that PD symptoms are no longer tolerable without levadopa treatment
(e.g., how soon a subject initiated medication after baseline). Another marker is the REM sleep
scores measuring sleep disorders that reflects evolving neural degeneration (Stiasny-Kolster et al.,
2007). In Figure 3.6, we compute the correlations between each of the two external variables and
observed symptoms (shaded gray), fitted symptoms (yellow) and fitted inflection point shift scores
(blue) respectively. We observe that across almost all markers, the correlations with external vari-
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ables are improved using MEFF fitted results (i.e., fitted symptom scores or shift scores). Higher
correlations with external variables of clinical importance indicate the evidence that the MEFF has
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Correlation with REM sleep scores
Figure 3.6: Correlation between each of the external variables (i.e., medication length and sleep
mean score) and observed subject-and-marker-specific symptom scores (shaded gray), fitted symp-
tom scores (yellow) and fitted shift scores (blue) respectively. The fitted results have higher corre-
lation with the external variables (i.e., yellow and blue bars), indicating enhanced signals by fitting
the MEFF model.
Besides posterior estimates for latent variables W and u, the fixed effects parameters from
MEFF are also informative for learning disease progression, especially for identifying early dis-
ease markers. To understand the disease progression only for patients, we fit the MEFF for PD
patients excluding healthy controls. Figure 3.7 shows the population-average marker trajectories
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represented by the probability of having mild or normal symptoms for 7 ordinal markers selected
from MDS-UPDRS and 6 continuous markers selected from cognitive and DaTscan imaging do-
main. As age increases, the probability of having normal symptoms decreases and equivalently the
disease severity increases. The dashed line indicates the population-averaged inflection point age
µk and the slope of the curve indicates the rate of impairment bk. For a marker to be useful for
early diagnosis, it should have relatively early inflection point age and large rate of impairment.
Figure 3.7a and Figure 3.7b show that MDS-UPDRS items are more useful for early diagnosis than
cognitive markers. Specifically, global spontaneity of movements (NP3BRADY) and facial expres-
sion (NP3FACXP) degenerate earlier in the disease course, which is consistent with a recent study
(Prashanth and Roy, 2018) and the clinical observations of PD (Jankovic, 2008). Among cognitive
and imaging markers, the putamen area has the earliest inflection point age and the largest rate of
impairment, followed by the caudate. These findings corroborate the current PD diagnosis which
heavily relies on MDS-UPDRS and DaTscan imaging measures. Furthermore, for early screening,
neurologists may pay more attention to global spontaneity of movements, facial expression, and
putamen area degeneration.
3.6 Discussion
In this work, we propose MEFF model to integrate multi-domain data to learn lower-dimensional
latent space of disease impairment, cluster patients in homogeneous groups, and characterize tem-
poral ordering of clinical and biological markers of PD neurodegeneration. Since neurodegener-
ation rarely follows a linear trend and patient heterogeneity cannot be sufficiently described by a
single set of latent variables, the MEFF takes a nonlinear form with multiple levels of latent vari-
ables. Computational challenges of optimizing multi-level nonlinear models are resolved by BBVI
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(b) Cognitive and DaTscan markers
Figure 3.7: Estimated mean progression trajectories using estimated probability of having mild or
normal symptoms. The dashed lines represent the locations of the corresponding inflection point
age µk shared across PD patients (lines for inflection point age larger than 90 are omitted). Mark-
ers including global spontaneity of movements, facial expression, caudata and putamen clearly
indicate evidence of early progression.
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which can handle a large number of observations and heterogeneous distributions.
The MEFF models have several practical utilities. First, the model allows predictions of future
disease progression and prognosis for individuals. Second, the model reduces the dimensionality of
a large number of markers to lower-dimensional latent factors to allow partitioning of patients into
homogeneous groups. Third and importantly, it provides a way to understand the interplay between
different domains of impairments. For example, the models will quantifiy change of markers (i.e.,
rate of impairment bk) during any given time period, and thus provide a ranking of markers with
more rapid and sensitive changes. This feature allows investigators to choose a marker to be tested
as a more effective intervention target in clinical trials using relatively smaller sample sizes and
short periods of time.
There are a few limitations of BBVI used to fit MEFF. First, the approximation to the targeted
posterior distributions may not be tight (Blei et al., 2017). There exist tighter lower bounds that
give better approximations than the one in VI (Opper et al., 2005). However, comparing to exact
optimization techniques such as MCMC and EM, VI has easy convergence criteria to access, and
the computational gain is substantial for the applications we consider. Second, similar to many
nonlinear and non-convex optimization procedures, the VI algorithm may converge to a local op-
timum, and the estimation process may be sensitive to initial values. For our analysis of PPMI,
multiple initial values were examined to ensure better convergence.
For practical utility, we can consider a few modifications on how we can apply the model
depending on the research questions of interest. First, trying to learn the global shared latent factor
common to all modalities may be too restricted and may not yield useful results if one or more
modalities do not contain valuable information. In this case, we can allow the model to learn
partially joint structure through factors shared by a subset of modalities of data. Prior knowledge
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is needed to determine which modalities may have more partially shared information and which
modalities are more isolated from the others. If clinical knowledge is not yet available, we can also
run MEFF including all modalities as an exploratory step, and determine the modality structures
through fitted results. For example, from our fitted results in Section 3.5.2, we know the cognitive
markers have little correlations with the other modalities. Another complexity worth noting is the
different impacts of modalities on modeling due to different numbers of markers belonging to each
modality. It is true that the modality with a very large number of markers will dominate the fitted
results. To balance out the effects from imbalanced number of markers, we can consider a weighted
likelihood with weights inversely correlated with the number of markers in each modality.
A few extensions of MEFF are worth consideration. To directly account for patient heterogene-
ity using subgroups, a Gaussian mixture model for ui with a Dirichlet prior for group membership
can be simultaneously incorporated in the model. To identify mechanisms through which putative
causal mutations (e.g., LRRK2 genotype for PD, APOE for AD) confer risk for a disorder (e.g.,
onset of PD or cognitive impairment), it is crucial to demonstrate that the markers as intermedi-
ate outcomes indicate disease progression and are on the pathway from genetic predisposition to
neuropathology. However, since gold standard disease diagnosis does not exist unless an autopsy
is performed for neuropathologic confirmation, using clinical diagnosis or milestone events of dis-
ease progression based on symptoms provides an alternative way to evaluate a marker’s validity.
For the MEFF, an extension is to consider jointly model the longitudinal markers and time-to-event
outcomes of critical clinical events (e.g., diagnosis of disease, initiation of PD treatments). Under
the MEFF and BBVI framework, a time-to-event outcome can be included through semiparametric
(e.g., Cox proportional hazards model) or parametric survival model. Lastly, when it is unknown
which domain a new marker belongs to, one can consider clustering markers based on extensions
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of MEFF. For example, a method for discovering domain structure for all markers can be developed
along the lines of topic modeling.
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Chapter 4
A Latent State-Space Model for Estimating Brain Sources and Connectivity
using EEG Data
4.1 Introduction
EEG, as a neuroimaging technique measuring electrical voltages in brain, serves as an increasingly
useful tool to investigate brain functions and understand neurological diseases. It is important to
model and interpret the observed multi-channel EEG signals with considerations of the dynamics
of the latent sources that generate the signals.
There is a large body of literature on brain source reconstruction from EEG signals. With an
appropriate head model that describes the geometrical characteristics of the head and 3D positions
of electrodes, and a source model that contains information about the location of dipole sources,
one can obtain a lead field matrix that describes how the brain sources are distributed to the sensors
(Hassan and Wendling, 2018; Baillet et al., 2001). The next step is to solve a linear inverse problem
to discover the underlying source signals. However, these brain source reconstruction approaches
require unknown physiological information on the lead field matrix that can vary from subject to
subject.
In contrast, statistical models and machine learning methods are proposed to study spatial
patterns of brain signals in a data-driven fashion. For example, ordinary differential equations
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(ODEs) are utilized to analyze multi-channel EEG data by modeling all signals as a system linked
by additive differential equations (Chen et al., 2017) or under a Bayesian framework (Zhang et al.,
2017). Semiparametric nonlinear dynamical systems under a single-index model framework are
proposed to relax the additive assumption (Sun et al., 2020). The dynamical system-based methods
pose assumptions on the derivatives of neural signals and require solving a system of ODEs, which
can be sensitive to initial conditions and subject to model misspecification. Hidden Markov models
have also been used to capture brain activity through combinations of a finite number of hidden
states to examine transitions among states (Williams et al., 2018). As a related approach, latent
state space models were proposed to analyze single-subject EEG data by expressing observed noisy
signals as outcomes arising from low-dimensional latent underlying sources (Li et al., 2019a).
A limitation of the existing methods is that they do not take into account inter- and intra-subject
differences in multiple-subject EEG studies, which reduces generalizability of their findings. High
between-subject variations are frequently present in EEG studies. These variations may originate
from individual differences in cortical mapping and/or mental functioning, giving rise to observed
differences in spatial and temporal patterns of EEG signals. Recent research has shown that the
between-subject variations can be captured using EEG data. For example, Hassan and Wendling
(2018) investigated the effect of subjects’ cognitive statuses on alterations of their functional brain
connectivity measured by EEG. They demonstrated that the brain networks identified by an EEG
source connectivity analysis can distinguish Parkinson’s disease patients with different degrees
of cognitive impairment. However, since the model did not involve any subject covariates, it is
difficult to quantify the association between EEG signals and the cognitive impairment.
In this work, we propose a novel method to analyze multi-channel EEG data measured inten-
sively at a high temporal resolution from multiple subjects. Our approach is different from the
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previous attempts to separate brain sources using multi-subject data. A key contribution of our
method is to borrow information from spatially correlated but noisy EEG measurements to en-
hance signals and account for between-subject heterogeneity. Specifically, the method uses latent
state space models in which the latent dynamic processes can accommodate subject covariates to
learn connectivity among the lower-dimensional states of brain cortical activities through a data-
driven approach. Constraints are placed on the connectivity matrix of the latent states to ensure
identifiability and to understand the interactions between brain sources for certain patient groups
defined by the covariates. The higher-dimensional observed EEG signals are modeled as a linear
projection of the latent states from which we can estimate the correlation between each latent state
and each observed EEG channel.
Computationally, an Expectation–maximization (EM) algorithm coupled with Kalman filter
and Kalman smoother is used to fit the latent state space model. We perform extensive simulation
studies to examine the performance of the proposed method. The approach is applied to a case-
control study of alcoholism to quantify differences of brain cortical activities between cases and
controls in the latent space. The analysis reveals distinct spatial patterns of expressions of latent
signals in alcoholic subjects and controls and identifies the differences between visual stimuli
conditions.
4.2 Methods
4.2.1 Latent State Space Model
Let Yi(tj), a K-dimensional vector, denote the sensor data collected from K scalp electrodes at
time tj , for j = 1, ..., J of the i-th subject. A commonly used sensor model (forward model or
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observation model) to describe the observed EEG signals is
Yi(tj) = ΘMi(tj) + εi(tj), εi(tj) ∼ N(0,Σi), (4.1)
where Mi(tj) = (Mi1(tj), ...,MiL(tj))> is an L-dimensional (L < K) vector representing the
latent states. Under this model, the signals collected by the electrodes are generated by L sources
of the brain underlying states Mi(tj), where a K × L weight matrix Θ describes how the lower-
dimensional latent states Mi(tj) are linearly projected onto the higher-dimensional observable
sensor outcome space. Here εi(tj) is independent background white noise with its variance de-
pendent on each subject. This residual accounts for the remaining variance of Yi(tj) that is not
explained by the latent brain states. To model dynamics of the underlying latent states Mi(tj), we







p Xi)Mi(tj−p) + γ
TUi(tj) + Wi(tj), (4.2)
Wi(tj) ∼ N(0,Σw),
where Xi is a vector of observed time-invariant covariates (e.g., demographics), Ui(t) is an ob-
served time-dependent covariate (e.g., intervention or change of experiment paradigm), and Wi(tj)
is independent Gaussian noise.
The connectivity matrix Ap with dimensions L × L represents how a single dimension of
latent state Mil(tj) evolves depending on its own p-step lagged preceding state Mil(tj−p) and the
p-step lagged preceding states of other dimensions, Mi,−l(tj−p). For example, in a first-order
MVAR model, a diagonal matrix A1 implies that the progression of Mil(tj) is independent of
other components of Mi. The parameter αp quantifies the effect of a subject covariates Xi on the
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the latent states Mi. A nonzero αp indicates that Xi has an effect on enhancing or attenuating
Mi over time. In summary, we can characterize interactions between latent sources and how these
interactions are associated with covariates using Ap and αp.
The sensor/observation model (4.1) and state model (4.2) form the basis of latent state space
models for EEG signals. To ensure stability that Mi(tj) does not explode to infinity, we require
that all the eigenvalues of Ap exp(α>p Xi) to be less than or equal to one (Boots et al., 2008). With
random variablesW i(tj) included, the model does not degenerate (Murphy, 2012). For simplicity,
the rest of this exposition mostly assumesm = 1. Extensions to models with higher orders does not
incur any technical difficulties since they can always be reduced to a simplified first-order model.
For example, for a model with order m = 2, the state model can be written as












 , A∗i =
A1 exp(α>1 Xi) A2 exp(α>2 Xi)
IL×L 0L×L










In our proposed model, the number of parameters increases with the dimensions of Yi(tj), Mi(tj)
and the number of covariates. To examine identifiability, first notice that we can restrict Σw to be I
without loss of generality. In addition, we assume that Σi in model (4.1) to be σ2i I to reduce number
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of parameters in order to increase numeric stability (Murphy, 2012). The residual covariance
matrix Σi can be extended to a diagonal matrix with different variance for each dimension at the
cost of increased number of parameters. With these constraints imposed, however, the parameters
are still only identifiable up to a rotation similar to other factor models. To see this, notice that
there exists an orthogonal matrix R, such that
Yi(tj) = ΘR
−1RMi(tj) + εi(tj) = Θ
∗M∗i (tj) + εi(tj), εi(tj) ∼ N(0, σ2i I).
RMi(tj) = RAR
−1RMi(tj−1) exp(α
>Xi) + RγUi(tj) + RWi(tj), Wi(tj) ∼ N(0, I)







i (tj) ∼ N(0, I)
with
Θ∗ = ΘR−1, M∗i (tj) = RMi(tj), A
∗ = RAR−1, γ∗ = Rγ. (4.4)
Hence, the parameters are identifiable up to some arbitrary orthogonal matrix R. To ensure that
all the parameters and the latent states are identifiable up to the sign and have meaningful inter-
pretations, we impose two more constraints for Θ. That is, Θ is required to have upper triangular
entries being 0 and its first column having norm one. Under these constraints, the first electrode
loads solely onto the first component of Mi(t) and each additional dimension of Mi(t) explains
additional shared variance of the observed EEG signals. Thus, the first component of Yi(t) serves
as a reference electrode, and the first column of the weight matrix Θ reflects the contribution from
the first latent source in Mi(t) to allK observed EEG electrodes. Similarly, additional components
of Mi(t) explain the remaining variances among all K − 1, · · · , K − L electrodes.
With the above two constraints, we can first obtain the parameter estimates from an EM algo-
rithm described in the next section. Then we will get the rotation matrix R using QR decomposi-
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tion on Θ∗, whose estimates are directly obtained from EM. Finally, we will apply transformations
described in (4.4) with R and normalize to estimate the identifiable parameters.
4.2.3 Estimation
Typically, the observation model (4.1) and the state model (4.2) can be estimated using a two-stage
approach, where we first fit an inverse model followed by a latent state space model (Babiloni
et al., 2005). However, Cheung et al. (Cheung et al., 2010) showed that the estimators derived
from this two-stage approach would be biased, especially when the signal-to-noise ratio is low.
In control theory, Kalman filter is a useful technique to estimate dynamics of latent states given
fixed parameters (e.g., (A,α,Θ)) and observed data. It is computationally efficient and accurate
if there is prior knowledge about the true values of the parameters in the model. However, this
is not the case for EEG studies since the mechanisms of how the brain transmits source signals
remains obscure. Therefore, we do not assume system parameters (A,α,Θ) to be known but
make use of EM algorithm that estimates the parameters in the presence of latent states. The
Kalman filter equations compute expected latent states at time tj conditioning on the previous
observed data (Yt1 , ...,Ytj−1), and the Kalman smoother equations compute expectation values at
time tj conditioning on all the observed data (Yt1 , ...,YtJ ). We use both equations to compute
conditional expectations of the latent states given observed data in the E-step.
4.2.3 Kalman Filter and Kalman Smoother Equations
Kalman filter and Kalman smoother are often used to compute the conditional expectation and
covariances for updating E-steps in latent state space models. Using the Kalman filter equations
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(Douc et al., 2014) based on the linear models (4.1) and (4.2), we have
Mij|j−1 ≡ E(Mi(tj)|Yi(t1) · · ·Yi(tj−1))
= AMij−1|j−1 exp(α
TXi) (4.5)
P ij|j−1 ≡ Cov(Mi(tj),Mi(tj−1)|Yi(t1) · · ·Yi(tj−1))
= AP ij−1|j−1A
T exp(2αTXi) + Σw (4.6)
with
Mij|j ≡ E(Mi(tj)|Yi(t1), · · · ,Yi(tj))




P ij|j = Var(Mi(tj)|Yi(t1), · · · ,Yi(tj))




ei(tj) = Yi(tj)−ΘMij|j−1 (4.9)


















j|J − P ij|j−1)J i>j−1
where








Let M0|0 = µ0i and P0|0 = Σ0i to be the mean and covariance parameters of the initial states
Mi(t0) for the subject i. Then the parameters to be estimated in the EM include (µ0,1:N , Σ0,1:N ,A,Θ,Σw,Σε).
Denote all these parameters as Ψ. The latent variables are the latent states M1:N,0:J . First, the com-
plete data log-likelihood assuming one can observe the latent states is




































In the E-step, using the result from the Kalman smoother, we can evaluate
Q(Ψ; Ψ(t−1)) ≡ E
[












0|J − µ0i)(Mi0|J − µ0i)>]
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(Yi(tj)−ΘMij|J)(Yi(tj)−ΘMij|J)> + ΘP ij|JΘ>
]}}
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In the M-step, it is easy to derive estimates of all the parameters that maximize Q(Ψ; Ψ(t−1)).
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However, since there is no closed form for α̂, we estimate it in the M-step using the New-
ton–Raphson method numerically. The above algorithm iterates between the E-step and M-step
until convergence.
4.2.4 Bootstrap and Testing
In addition to point estimation, it is crucial to evaluate the variability of parameter estimates in or-
der to make useful statistical inference. Stoffer and Wall (Stoffer and Wall, 1991, 2004) proposed a
bootstrap method to provide sampling distributions of estimators in state space models under gen-
eral conditions. Applying this method to our models (4.1) and (4.2), the procedure for generating
a bootstrap data set can be summarized as the following:
1. Compute the standardized innovations ẽi(tj) = (Σ̂itj)
−1/2êi(tj) for all subjects i = 1, ..., N
and all time points j = 1, ..., J with parameters in (4.9) and (4.10) replaced by their esti-
mates.
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2. For each subject i, the bootstrap samples of standardized innovations {ẽ∗i (t1), ..., ẽ∗i (tJ)} are
obtained by first sampling a subject index i∗ with replacement , and then sampling J times
from {ẽi∗(t1), ..., ẽi∗(tJ)} with replacement .
3. For each subject i and time point j, calculate estimates M̂ij|j−1 using (4.5) and (4.7) with
parameters replaced by estimates and ei(tj) replaced by ẽ∗i (tj). Then construct bootstrap




i (tj) for all subjects and time points.
Each bootstrap data provides a new set of parameter estimates. We repeat the above process B




We conducted simulation studies to evaluate the estimation accuracy and variability of our method.
To ensure that our model can capture true signals in real applications, we simulated data sets using
parameters close to their estimated values in a real-world study described in Section 4.4. EEG
sensor measurements of 20 channels were assumed to be measured at 256Hz and generated from
two underlying latent neuronal states. Each simulated data set contained simulated EEG time se-
ries for 20 subjects. As described in Section 4.2.1, we included Xi to investigate the effects of
subject characteristics on how the latent states evolve over time, andαp is the parameter of interest
to quantify this effect. In this simulation study, Xi is a binary variable indicating a dichotomous
feature (e.g., subject’s case/control status). We explored different scenarios by setting αp to dif-
ferent values including 0. We noted that αp should take some small values in order to maintain
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stability of the latent states M. In the latent state space model (4.2), the order m can be any integer
suitable for the real data. Here we present results with m = 1 for simplicity. Results for a model
with m = 2 are shown in Appendix B, Figure B.2. Section 4.3.2 describes the results from 100
simulated data sets under the scenario of m = 1 and α = −0.05, where α took a similar value as
estimated from the real data. The true values for Θ were generated from a standard normal distri-
bution with its upper triangular entry (i.e., entry of first row second column) constrained to be 0
and the first column-wise norm constrained to be 1. We also generated the measurement noise with













































































































Figure 4.1: Boxplots of biases of the estimates A, α and Θ from 100 simulated data sets generated
from the model with m = 1, α = −0.05 and σ2i = 5, 1.
73
4.3.2 Simulation Results
Figure 4.1 shows the boxplots of the biases for the estimated parameters in the connectivity matrix
A and α from their true values using 100 simulation replicates under the model (4.1) and (4.2)
with m = 1 and two levels of measurement noises. From the figure, we see that overall the biases
of the five parameter estimates for A and α are small with reasonable standard errors, indicating
that the model can accurately recover temporal dynamics of the latent sources and between-group
difference. The biases and standard errors for α̂ and Â do not necessarily decrease significantly
with a smaller variance of measurement errors because they are associated with latent states. The
measurement error variance affects the standard error of Θ̂ in the measurement model (4.1) more
than α̂ and Â. For the parameter α representing case/control group differences, the true value (i.e.,
α = −0.05) used in the simulation is close to the estimated value from the real data. The mean
absolute bias of α̂ under σ2i = 5 is 0.015 with the standard error 0.019. When σ
2
i decreases to 1, the
mean absolute bias of α̂ is 0.016 with the same standard error. To examine the coverage probability
for α, we followed the procedure in Section 4.2.4 to generate bootstrap samples for each simulated
data using standardized innovations and computed bootstrap confidence interval. The empirical
coverage probability for confidence interval of α is estimated to be around 95%.
The estimates for Θ of dimensions 20 by 2 indicate how the two latent neuronal states are
distributed at the corresponding observed EEG signals. The biases of the estimates are also shown
in Figure 4.1. All the estimates of Θ are accurately estimated with small biases and standard
errors. It is apparent that the standard errors of Θ̂ decrease under measurement noise with a
smaller variance. The bootstrap replicates on each simulated data also reveal that the coverage
probabilities are overall around 95% for Θ. When using 0 as the true value for α to simulate data,
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similar results can be observed. The biases for estimates of A, α and Θ are small. The coverage
probability for the parameter of interest α is around 95%, indicating that the type I error for testing
H0 : α = 0 will be controlled around 0.05.
We also run simulations for models with a second order auto-regressive structure for Mi(t),
i.e., m = 2, α1 = −0.05 and α2 = −0.08. Under measurement noise with variance σ2i = 5, the
mean absolute bias for α̂1 and α̂2 is 0.010 (s.e 0.012) and 0.017 (s.e 0.021) respectively. Under
noise of variance σ2i = 1, both biases and standard errors remain at similar values. Biases of θ̂ are
small and the standard errors decrease as the variance of noise decreases. The results are shown in
Appendix B, Figure B.2.
4.4 Real Data Application
The state-space model was applied to an EEG study of alcoholism (Asuncion and Newman, 2007).
In this EEG experiment, 77 subjects at risk of alcoholism and 45 healthy controls were enrolled.
All subjects were exposed to three types of visual stimuli conditions: a single image (C1, sin-
gle condition), two identical repeated images (C2, matched condition) and two different images
(C3, non-matched condition) when EEG signals were recorded through 62 EEG electrodes with
a sampling rate of 256 Hz for one second (Asuncion and Newman, 2007). Multiple trials were
conducted for each subject under each visual stimulus condition. Zhang et al. (1995) described
in detail the data collection process and applied multivariate analysis of variance (MANOVA) to
demonstrate the differences of EEG signals under C2 and C3 in terms of latency and amplitude
of the event related potential (ERP) component (c247). We applied our method to quantify the




Several general patterns can be observed from the exploratory analysis. To remove single-trial
artifacts and reduce unwanted noise, we first took a grand mean average for each subject across
available trials for each visual stimulus condition. Next, we applied a first-order difference filter
to the subject-level EEG signals. It is standard to use a differencing operator to eliminate artificial
trends and improve stationarity of time series data (Chatfield and Xing, 2019). The rest of the
paper will refer to the EEG signals after taking a first-order difference as EEG outcomes. We
can visualize the data in Figure 4.2, where observed EEG outcomes are shown for three channels
(Fz, CP4 and PO2) under matched conditions (C2) and for case and control subjects separately.
The corresponding average outcomes across all the cases or controls were also shown as a time
series below each heat map. Figure 4.2 shows that channels CP4 and PO2 both have prominent
decreasing and increasing trends evoked by visual stimuli between 0.1 and 0.3 seconds, while this
is less so for the Fz channel.
Figure 4.3 shows the averaged EEG outcomes under three visual stimuli conditions for all the
channels. Each trajectory is an averaged outcome across cases or controls for a specific electrode,
with its location in the brain shown in the brain heat map. Figure 4.3 shows that the major channels
with larger peaks and dips, as a sign of being activated, are often related to the occipital lobes (O1,
O2, Oz), the parietal lobes (P1-P8) and the lobes between them (PO7, PO8, POz). Since the main
functions of the occipital and parietal lobes are for vision, they are expected to be activated by the
visual stimuli. The observed EEG signals can capture some of the true underlying neural activities
of interest. Comparing the signals for control subjects (right) with alcoholic subjects (left), we see
that controls have larger amplitude at these vision channels. This is consistent with prior findings
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Cases Controls
Figure 4.2: Heat maps of observed EEG outcomes under matched conditions (C2) for three selected
electrodes (Fz, CP4 and PO2) with each column representing a case or a control subject. Each time
series shows the averaged EEG outcome across all the case or controls, with a bootstrapped 95%
confidence band around the mean.
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that alcoholism is associated with lower-voltage recordings in EEG studies (Enoch et al., 1999).
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Figure 4.3: Observed EEG outcomes under the three visual stimuli (rows). Each trajectory repre-
sents a specific EEG channel averaged across 77 cases (left) or 45 controls (right) in the alcoholism
study. The location of the channel can be found through the node of the same color in the upper
left heat map.
4.4.2 Model Fitting
We simultaneously analyzed all 122 subjects in the alcoholic and control groups following the
steps described in Section 4.2. First, we considered the first-order MVAR using m = 1 for the
latent state space model. We excluded 6 channels (i.e., FP1, C1, C2, PO7, PO8 and FP1) due
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to high artificial noise observed in many trials. The remaining 56 channels were jointly fit in the
model. In model (4.1) and (4.2), the subjects’ EEG signals share the same spatial map Θ but have
their own latent state trajectories Mi(t). Since the main goal is to compare the differences between
cases and controls in terms of transitions of latent states Mi(t), we included a binary covariate Xi
to indicate case or control group. A nonzero estimate for α will quantify effects of Xi on how the
latent states evolve over time and connect with one another. Other covariates such as gender and
genetic information can also be included in other studies based on specific research hypotheses.
To determine L, the dimension of Mi(t) in the latent space, we fit the model with L being
1, 2, 3, 4 and 5 respectively. For each fitted EEG outcome of a subject, we obtained the mean
squared prediction error (MSPE) for which lower values indicate larger exploratory power of the
fitted model. In Appendix B, Figure B.3 shows boxplots of MSPE of fitted models using different
dimensions of latent states for all subjects. We can see that as the dimension of the model increases,
MSPE gets smaller overall due to increase in model complexity. However, since the decrease from
L = 3 to L = 4 is negligible, we chose L = 3 to fit the real data considering both model parsimony
and complexity. We repeated the model fitting for EEG outcomes from each of the three visual
stimuli conditions. We also obtained confidence intervals for each parameter estimate using the
same bootstrap procedure described in Section 4.3.
Assuming L = 3 (i.e., three latent states), the parameter estimates for A, α and their bootstrap
confidence intervals are shown in Table 4.1. Some significant off-diagonal terms of the connectiv-
ity matrix A suggest that the three states interact to give rise to the observed signals, although the
magnitude of the effect is not large. Under all three visual stimuli conditions, significant α esti-
mates suggest that subjects affected by alcoholism have attenuated latent states M as they evolve
over time compared to healthy controls. In Appendix B, Figure B.4 shows the three estimated
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latent states Mj|j−1 under each visual stimulus condition averaged across cases or controls. As
expected, controls generally have larger amplitudes of Mj|j−1 between 0.1 and 0.3 seconds while
alcoholic subjects have smaller ones. The parameter Θ describes the spatial pattern of how the 56
observable EEG outcomes are generated by the three underlying brain states. Its estimated values
are presented using heat maps in Figure 4.4. For estimates of Θ under C2, we also show the spatial
pattern associated with each latent factor in a topological map in Figure 4.5. It is apparent that
channels from pre-frontal (FP), frontal (F), between FP and F (AF), and between FP and central
(FC) mainly load on the first latent state (i.e., green lines in Figure B.4 ), while channels from
parietal (P), occipital (O), between P and O (PO), and between P and central (CP) mainly relate
to the third latent state (i.e., pink lines in Figure B.4). The second latent state (i.e., orange lines
in Figure B.4) has positive loadings with channels from the right brain (i.e., channels with names
containing even numbers), and negative loadings with channels from the left brain, suggesting that
this state models the contrast between the left and right brain regions. These patterns observed
in the estimated Θ values are consistent across visual stimuli conditions C1 to C3, with a slight
decrease in values corresponding to CP, P and PO lobes when comparing C2 and C3 with C1.
Since C2 and C3 used more complex stimuli (i.e., multiple matched or non-matched pictures), it
is expected that they solicit more activation from the higher order cognitive function regions (e.g.,
frontal and parietal lobes).
Figure 4.6 shows the fitted EEG outcomes using Θ̂M̂j|j−1 averaged across cases or controls.
Compared with the observed outcomes in Figure 4.3, we can see that our model recovers the main
stimuli-related signal patterns from 0.1 to 0.3 seconds. Moreover, the model removes excessive
noise and artifacts to generate smoothed outcome trajectories with clustering patterns. For condi-
tions C2 and C3 for both cases and controls, 56 channels can be observed to cluster in 7 groups
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Table 4.1: The parameter estimates for A and α in the models that fits EEG outcomes under the

















































































































Figure 4.4: Heat maps of the spatial patterns associated with each of the three latent factor repre-
sented by parameter estimates of Θ in the fitted latent state space model of EEG signals from the
alcoholism study under the three visual stimuli (columns).
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Figure 4.5: Topological maps of the spatial patterns associated with each of the three latent factor
represented by parameter estimates of Θ in the fitted model from the alcoholism study under visual
stimulus C2.
at the peak (Figure 4.6). The clustering membership highly correlates with the positions of corre-
sponding electrodes, shown by the similar trajectory colors in each cluster. Figure 4.6 also presents
the topological heat maps at 4 time points when EEG outcomes reach local minima or maxima.
We can see the presence of a much stronger signal in controls compared with cases, as confirmed
by the significant difference in latent states represented by α. As sensitivity analysis, we also show
the fitted EEG outcomes under C2 using L = 1, 2 and L = 4. The results (Figure B.5) show that
L = 1 does not adequately capture all observed variations in EEG outcomes, while L = 4 does not
provide additional improvement in the fitted signals. Models with L = 2 or L = 3 show similar fit
of outcomes, but MPSE shows a decrease in error for L = 3 (Figure B.3), supporting the choice of
three latent states.
In conclusion, we have identified three distinct latent states for modeling whole brain EEG dy-
namics (Figure B.4): one state represents frontal and pre-frontal areas; one represents parietal and
occipital areas, and one for left-right region contrast. We also estimated a significant attenuating



























Figure 4.6: Fitted EEG outcomes under the three visual stimuli (rows), with topological heat maps
at 4 time points. Each trajectory represents a model-fitted EEG channel averaged across 77 cases
(left) or 45 controls (right) in in the alcoholism study.
4.5 Discussion
In this work, we propose a latent state space model that incorporates subject covariates to model
multi-subject EEG signals. Our model can accommodate a large number of electrodes in the
observation model while using lower-dimensional latent states to represent high-dimensional ob-
servations. The correlated spatial patterns are captured by the observation model and the temporal
83
patterns are captured by the MVAR of the latent states. An EM algorithm coupled with Kalman
filter and Kalman smoother is proposed to fit the model, and bootstrap is used to perform inference.
It has been shown that the model is effective in removing noise and revealing differential patterns
for alcoholic subjects and healthy controls.
Our method can be extended in multiple ways. Our exposition here considers a few covariates.
When high-dimensional covariates are available (e.g., genomic measures), their effects on latent
states may be modeled in a similar fashion with sparsity-induced regularization. The proposed
method assumes stationary time series data. For applications where non-stationary is suspected,
we may allow the connectivity matrix A to vary with time, and estimation can proceed with a
sliding-windows approach. Alternatively, switching state space models (Ghahramani and Hinton,
2000) can be considered, where the underlying latent sources are assumed to switch from a few
unobserved states at different segments of time. Here we chose the number of latent states by
empirically examining models fitted under a different number of states. The optimal choice of a
number of latent states remains an open research question. In practice, information criterion such
as AIC or BIC can be considered.
The observation model under lower triangular constraint in Section 4.2.1 is a data-driven model
that does not incorporate underlying physics or brain anatomy involved in EEG signal measure-
ments. Alternatively, source reconstruction methods perform dipole source localization by esti-
mating one or more source dipoles that can be relocated within the brain from measured scalp
EEG signals (Cheung et al., 2010; Haufe et al., 2008, 2011). For example, in a suitable forward
model of EEG data (the model describing how neural activity in the brain maps to the EEG sen-
sors) and under some static assumption of EEG frequencies, the forward matrix relates sensor data
and neural source activity as Yi(t) = HMi(t) + εi(t), where H is the known lead field matrix
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for distinct locations on the cortical surface. Computation of the lead field matrix may account for
brain anatomy and geometries of various tissue compartments in the head (e.g., gray matter, white
matter, cerebrospinal fluid). Combining this observation model with the latent state model (4.2)
may yield anatomically interpretable latent states.
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Chapter 5
Survival-Convolution Models for Predicting COVID-19 Cases and Assessing
Effects of Mitigation Strategies
Acknowledgement: This chapter is derived in part from an article published in Frontiers of Public
Health (Wang et al., 2020b).
5.1 Introduction
COVID-19 pandemic is currently a daunting global health challenge. The novel coronavirus was
observed to have a long incubation period and highly infectious during this period (Li et al., 2020b;
Gates, 2020; Bai et al., 2020; Ganyani et al., 2020). The cumulative case number surpasses 4.1
million by May 10, with more than 1.3 million in the United States (US). It is imperative to study
the course of the disease outbreak in countries that have controlled the outbreak (e.g., China and
South Korea) and compare mitigation strategies to inform decision making in regions that are in
the midst of (e.g., the US) or at the beginning of outbreak (e.g., South America).
Various infectious disease models (Guo et al., 2020; Li et al., 2019b; Jovanović and Krstić,
2012) are proposed to estimate the transmission of COVID-19 (Wu et al., 2020; Li et al., 2020c;
Kucharski et al., 2020; Du et al., 2020; Li et al., 2020a) and investigate the impact of public health
interventions on mitigating the spread (Koo et al., 2020; Ferguson et al., 2020; Tian et al., 2020;
Flaxman et al., 2020; Prem et al., 2020). Several studies modeled the transmission by stochastic dy-
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namical systems (Li et al., 2020c; Wu et al., 2020; Kucharski et al., 2020; Tian et al., 2020), such
as susceptible-exposed-infectious-recovered (SEIR) models (Wu et al., 2020), extended Kalman
filter (Ionides et al., 2006; Cazelles and Chau, 1997; Dureau et al., 2013), and individual-based
simulation models (Ferguson et al., 2020; Koo et al., 2020). Some models did not explicitly take
into account of behavioral change (e.g., social distancing) and government mitigation strategies
that can have major influences on the disease course, while other work modified the transmission
rate as public-health-intervention-dependent (Tian et al., 2020; Prem et al., 2020) or time-varying
(Kucharski et al., 2020). A recent study (Flaxman et al., 2020) considered the disease incuba-
tion period and used a convolution model based on SEIR. A state-space susceptible-infectious-
recovered (SIR) model with time-varying transmission rate (Song et al., 2020) was developed to
account for interventions and quarantines.
SEIR models can incorporate mechanistic characteristics and scientific knowledge of virus
transmission to provide useful estimates of its temporal dynamics, especially when individual-
level epidemiological data are available through surveillance and contact tracing. However, these
sophisticated models may involve a large number of parameters and assumptions about individual
transmission dynamics. Thus, they may be susceptible to perturbation of parameters and prior
assumptions, yielding wide confidence intervals especially when granular individual-level data are
not available. In contrast to infectious disease models, alternative statistical models are proposed
to predict summary statistics such as deaths and hospital demand under a nonlinear mixed effects
model framework (IHME et al., 2020), survival analysis has been introduced to model the occur-
rence of clinical events in infectious disease studies (Cole and Hudgens, 2010), and a nonparamet-
ric space-time transmission model was developed to incorporate spatial and temporal information
for predictions at the county level (Wang et al., 2020a). Nonparametric modelling or survival
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models are data-driven, so parameters may not be scientifically related to disease epidemic.
In this work, we propose a parsimonious and robust population-level survival-convolution
model that is based on main characteristics of COVID-19 epidemic and observed number of con-
firmed cases to predict disease course and assess public health intervention effect. Our method
models only key statistics (e.g., daily new cases) that reflect the disease epidemic over time with
at most six parameters, so it may be more robust than models that rely on individual transmission
processes or a large number of parameters and assumptions. We construct our model based on
prior scientific knowledge about COVID-19, instead of post-hoc observations of the trend of dis-
ease spread. Specifically, three important facts we consider include (1) SARS-CoV-2 virus has an
incubation period up to 14-21 days (Li et al., 2020b) and a patient can be highly infectious in the
pre-symptomatic phase; (2) transmission rate varies over time and can change significantly when
government guidelines and mitigation strategies are implemented; (3) intervention effect may be
time-varying.
We aim to achieve the following goals. The first goal is to fit observed data to predict daily
new confirmed cases and latent pre-symptomatic cases, the peak date, and the final total number
of cases. The second goal is to assess the effect of nationwide major interventions across countries
(e.g., mitigation measures) under the framework of natural experiments (e.g., longitudinal pre-post
quasi-experimental design (Leatherdale, 2019)). Quasi-experiment approaches are often used to
estimate intervention effect of a public health intervention (e.g., HPV vaccine (Smith et al., 2015))
or a health policy where randomized controlled trials (RCTs) are not feasible. Our third goal
is to project the future trend of COVID-19 for the countries (e.g., US) amid the epidemic under
different assumptions of future transmission rates, including the continuation of the current trend




We used data from a publicly available database that consolidates multiple sources of official re-
ports (World Meters [https://www.worldometers.info/coronavirus/]). We ana-
lyzed two countries with a large number of confirmed cases in Asia (China, South Korea) and two
outside (Italy, US). Since both China and South Korea are already at the end of epidemic, we used
their data to test empirical prediction performance of our method. We included data in the early
phase of epidemic as training set to estimate model parameters and leave the rest of the data as test-
ing set for evaluation. For China, we used data up to two weeks post the lockdown of Wuhan city
(January 23) as training (data from January 20 to February 4), and used the remaining observed
data for evaluation (February 5 to May 10). Similarly, for South Korea we used data from February
15 to March 4 as training and leave the rest for evaluation (March 5 to May 10). Italy is the first
European country confronted by a large outbreak and currently has passed its peak. We estimate
the effect of the nation-wide lockdown in Italy (dated March 11) using 10 weeks data (February 20
to April 29). For the US, since after May 1 some mitigation measures were lifted in various states,
we also included about 10 weeks data (February 21 to May 1) to assess the effect of its mitigation
strategies.
5.2.2 Survival-Convolution Model
Let t denote the calendar time (in days) and let N0(t) be the number of individuals who are newly
infected by COVID-19 at time t. Let tj denote the time when individual j is infected (tj = ∞
if never infected), and let Tj be the duration of this individual remaining infectious to any other
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individual and in the transmission chain. Let t0 be the unknown calendar time when the first
patient (patient zero) is infected. Therefore, at time t, the total number of individuals who can
infect others is
∑




{j: j is infected at (t−m)} I(Tj ≥ m), where
C = min(t − t0, C1) with C1 as the maximum incubation period (i.e., 21 days for SARS-CoV-2)
and I(E) denotes an indicator function with I(E) = 1 if event E occurs and I(E) = 0 otherwise.
Since the total number of individuals who are newly infected at time (t − m) is N0(t − m), the
number of individuals who remain infectious at time t is M(t) =
∑C
m=0N0(t −m)S(m), where
S(m) denotes the proportion of individuals remaining infectious after m days of being infected, or
equivalently, the survival probability at day m for Tj . On the other hand, right after time t, some
individuals will no longer be in the transmission chain (e.g., due to testing positive and quarantine
or out of infectious period) with duration Tj = (t − tj). The total number of these individuals is∑








N0(t−m)[S(m)− S(m+ 1)]. (1)
Therefore, (M(t) − Y (t)) is the number of individuals who can still infect others after time t.
Assuming the transmission rate at t to be a(t), then at time (t + 1) the number of newly infected
patients is a(t)[M(t)− Y (t)], which yields




Note that a(t) is time-varying because the transmission rate depends on how many close con-
tacts an infected individual may have at time t, which is affected by public heath interventions
(e.g., stay-at-home order, lockdown), and saturation level of the infection in the whole population.
Define Rt =
∑C
m=0 a(t+m)S(m), the expected number of secondary cases infected by a primary
infected individual in a population at time t while accounting for the entire incubation period of
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the primary case. Thus, Rt is the instantaneous time-varying effective reproduction number (Cori
et al., 2013) that measures temporal changes in the disease spread.
Models (1) and (2) provide a robust dynamic model to characterize COVID-19 epidemic. Equa-
tion (2) gives a convolution update for the new cases using the past numbers, while equation (1)
gives the number of cases out of transmission chain at time t, and M(t) computes the number of
latent pre-symptomatic cases by the end of time t. This model considers three important quantities
to characterize COVID-19 transmission: the initial date, t0, of the first (likely undetected) case in
the epidemic, the survival function of time to out of transmission, S(m), and the transmission rate
over calendar time, a(t).
We model transmission rate a(t) as a non-negative, piece-wise linear function with knots placed
at meaningful event times. The simplest model consists of a constant and a single linear function
with three parameters (infection date of patient zero, intercept and slope of a(t)). When a massive
public health intervention (e.g., nation-wide lockdown) is implemented at some particular date, we
introduce an additional linear function afterwards with a new slope parameter. Thus, the difference
in slope parameters of a(t) before and after an intervention reflects its effect on reducing the rate of
change in disease transmission (i.e., “flattening the curve”). Since the intervention effect may di-
minish over time, we introduce another slope parameter two weeks after intervention to capture the
longer-term effect. We use existing knowledge of SARS-CoV-2 virus incubation period (Li et al.,
2020b) to approximate S(m) and perform sensitivity analysis assuming different parameters. For
estimation, we minimize a loss function measuring differences between model predicted and ob-
served daily number of cases. For statistical inference, we use permutation based on standardized
residuals. All mathematical details are in Supplementary Material.
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5.2.3 Utility of Our Model
First, with parameters estimated from data and assuming that the future transmission rate remains
the same trend, we can use models (1) and (2) to predict future daily new cases, the peak time,
expected number of cases at the peak, when Rt will be reduced to below 1.0, and when the epi-
demic will be controlled (the number of daily new cases below a threshold or decreases to zero).
Furthermore, our model provides the number of latent cases cumulative over the incubation period
at each future date, which can be useful to anticipate challenges and allocate resources effectively.
Second, we can estimate the effects of mitigation strategies, leveraging the nature of quasi-
experiments where subjects receive different interventions before and after the initiation of the
intervention. The longitudinal pre-post intervention design allows valid inferences assuming that
pre-intervention disease trend would have continued had the intervention not taken place and local
randomization holds (whether a subject falls immediately before or after the initiation date of
an intervention may be considered as random, and thus the “intervention assignment” may be
considered to be random). Applying this design, the intervention effects will be estimated as the
difference in the rate of change of the transmission rate function before and after an intervention
takes place.
Third, we study the impact of an intervention (e.g., lifting mitigation measures) that changes
the epidemic at a future date. Using permutations, we obtain the joint distribution of the parameter
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Figure 5.1: Observed and predicted daily new cases and 95% confidence interval (shaded). (A)
China. Training data: January 20 to February 4; testing data: February 5 to May 10. 14,108 cases
were reported on February 12 and not shown on figure. The recent cases since April are imported
cases. (B) South Korea. Training data: February 15 to March 4; testing data: March 5 to May
10. (C) Italy. First dashed line indicates the nation-wide lockdown (March 11). Second and third
dashed line indicates two or four weeks after. Training data: February 20 to April 29 (7 weeks
after the lockdown); testing data: April 30 to May 10.
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5.3 Results
For China, the transmission rate a(t) is a single linear function (estimates in Table 5.1). The first
community infection was estimated to occur on January 3, 17 days before the first reported case
(Table 5.1). Figure 5.1A shows that the model captures the peak date of new cases, the epidemic
end date, and the confidence interval contains the majority of observed number of cases except
one outlier (due to a change of diagnostic criteria). The reproduction number Rt decreases quickly
from 3.34 to below 1.0 in 14 days (Figure 5.2A). We only used data up to February 4 to estimate
our model. The observed total number of cases by May 10 is 82,901, which is inside the 95%
CI of the estimated total number of cases (58,415; 95% CI: (42,516, 133,083)). There are two
outlier days (February 12, 13) with a total of 19,198 cases reported in the testing set. Excluding
two outliers, the observed number of cases 62,356.
For South Korea, Figure 5.1B shows that the model captures the general trend of the epidemic
except at the tail area (after March 15) where some small and enduring outbreak is observed. The
effective reproduction number decreases dramatically from 5.37 at the beginning of the outbreak
to below 1.0 in 14 days (Figure 5.2B). The predicted number of new cases at the peak is 665 and
the total number of predicted cases at the peak time is close to the observed total (4,300 vs 4,335).
The predicted total number by March 15 is 7,816 and the observed total is 8,162.
For Italy, we model a(t) as a four-piece linear function to account for the change in mitigation
strategies with a knot placed at the lockdown (March 11), and two additional knots at 2-week
intervals (March 25, April 8) to account for time-varying intervention effect (during the immediate
2 weeks, next 2 weeks and afterwards). Difference on the rate of change before and after the first
knot measures the immediate effect of lockdown on reducing the transmission rate. Change before
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and after the second and third knot measures whether the lockdown effect can be maintained in
longer term. The rate of change in Rt is not significantly different before and two weeks after the
lockdown (Figure 5.2C). The reproduction number decreased from 3.73 at the beginning to 1.02
two weeks post-lockdown. However, starting from the third week post-lockdown (March 26), Rt
stops decreasing and remains close to 1.0 until April 16. The slope of a(t) increases by 116%
to a slightly positive value after March 26 (Table 5.1, comparing a2 and a3 for Italy). This is
consistent with a relatively flat trend of observed daily new cases during this period (Figure 5.1C).
The estimated total by May 10 is 216,300 (95%CI: (214,863, 228,406)) and close to the observed
total (219,070). Recent daily cases in the testing set also closely follow our predicted trend (Figure
5.1C).
In the US, we fit a three-piece model for a(t) with a knot on March 13 (the declaration of
national emergency) and an additional knot two weeks after (March 27) to account for potential
changes in the transmission rate. The predicted peak date is May 3 (Figure 5.3A) with a total num-
ber of 1,176,915 cases by May 3, which is close to the observed total (1,188,122). Rt increases
during the early phase but decreases sharply after the declaration of national emergency (Figure
5.3B) up to two weeks after. During the next period (March 28 to April 10), Rt decreases at a
much slower rate. If this trend continues, the end of epidemic date is predicted to be July 26 (sce-
nario 1, Figure 5.3A, Table 5.1). However, since states in the US are gradually lifting mitigation
measures after May 1, the trend of transmission rate may change. We predicted epidemic control
date assuming a(t) decreases slower after May 1 by 50% (scenario 2), 75% (scenario 3), and 100%
(scenario 4) in Table 5.1. Under scenario 4 where the temporal effect of mitigation measures is
completely lost (i.e., a(t) is a constant over time), the projected total number of cases will be more

































































Figure 5.2: Effective reproduction number Rt for each country computed as the average number
of secondary infections generated by a primary case at time t accounting for the incubation period
































































































Scenario 1 Scenario 2 Scenario 3 Scenario 4
(b)
Figure 5.3: United States: observed and predicted daily new cases, 95% confidence intervals under
four scenarios that assume relaxation of mitigation measures occurs after May 1. Scenario 1:
transmission rate a(t) follows the same trend after May 1 as observed between March 27 and May
1. Scenario 2: rate of decrease of a(t) slows by 50% after May 1. Scenario 3: rate of decrease of
a(t) slows by 75% after May 1. Scenario 4: rate of decrease of a(t) slows by 100% after May 1
(complete loss of temporal decreasing effect). First dashed line indicates the declaration of national
emergency (March 13). Second dashed line indicates two weeks after (March 27). Training data:
February 21 to May 1 (7 weeks after declaring national emergency); testing data: May 2 to May
10. (A) Observed and predicted daily new cases. (B) Effective reproduction number Rt.
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cases, Table 5.1). We provide an updated analysis of the US epidemic with more training data until
May 29 (Appendix C.1). The predicted recent trend is closer to scenario 4 with a control date in
November and a total cases of 2.7 million. Assuming a case fatality rate of 6% as observed by
May 10, the total number of deaths would be around 162,000 by November.
We show the estimated number of latent cases present on each day (i.e., including pre-symptomatic
patients infected k days before but have not shown symptoms) in Appendix C.1 (Figure C.1). For
all countries, there were a large number of latent cases around the peak time. We performed
a sensitivity analysis using different distributions of S(m) assuming a delay in reporting con-
firmed cases. The results show that predicted daily new cases were similar under different pa-
rameters of S(m) for both US and Italy (Appendix C.1 Figures C.2 and C.3), demonstrating ro-
bustness of our method to the assumptions of S(m). Our results of prediction for US is a part of
the CDC ensemble modeling group (https://covid.cdc.gov/covid-data-tracker/
#forecasting_weeklydeaths) that influences national COVID-related policies (Ray et al.,
2020).
5.4 Discussion
In this study, we propose a parsimonious and robust survival convolution model to predict daily
new cases of the COVID-19 outbreak and use a natural quasi-experimental design to estimate the
effects of mitigation measures. Our model accounts for major characteristics of COVID-19 (long
incubation period and highly contagious during incubation) with a small number of parameters (up
to six) and assumptions, directly targets prediction accuracy, and provides measures of uncertainty
and inference based on permuting the residuals. We allow the transmission rate to depend on time
and modify the basic reproduction number R0 as a time-dependent measure Rt to estimate change
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in disease transmission over time. Thus, Rt corrects for the naturally impact of time on the disease
spread. Our estimated reproduction number at the beginning of the epidemic ranges from 2.81 to
5.37, which is consistent with R0 reported in other studies (Liu et al., 2020) (range from 1.40 to
6.49, with a median of 2.79). For predicting daily new cases, our analyses suggest that the model
estimated from early periods of outbreak can be used to predict the entire epidemic if the disease
transmission rate dynamic does not change dramatically over the disease course (e.g., about two
weeks data is sufficient for China and fits the general trend of South Korea).
Comparing the effective reproduction numbers across countries, Rt decreased much more
rapidly in South Korea and China than Italy (Figure 5.2). In South Korea, the effective repro-
duction number had been reduced from 5.37 to under 1.0 in a mere 13 days and the total number
of cases is low. The starting reproduction number in South Korea was high possibly due to many
cases linked to patient 31 and outbreaks at church gatherings. Similarly for China, the reproduc-
tion number reduced to below 1.0 in 14 days. Italy’s Rt decreased until almost reaching 1.0 on
March 25, but remained around 1.0 for 3 weeks. The US followed a fast decreasing trend during a
two-week period after declaring national emergency (a2 = −1.031), which is faster than the first
two weeks in China (a1 = −0.693), but its Rt decreased at a much slower rate (a3 = −0.042)
afterwards and was below 1.0 on May 5.
Comparing mitigation strategies across countries, the fast decline in Rt in China suggests that
the initial mitigation measures put forth on January 23 (lockdown of Wuhan city, traffic suspension,
home quarantine) were successful in controlling the transmission speed of COVID-19. Additional
mitigation measures were in place after February 2 (centralized quarantine and treatment), but did
not seem to have significantly changed the disease course. In fact, our model assuming the same
transmission rate trajectory after February 2 fits all observed data up to May 10. A recent analysis
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of Wuhan’s data (Pan et al., 2020; Hartley and Perencevich, 2020) arrived at a similar conclusion,
and their estimated Rt closely matches with our estimates. However, their analyses were based
on self-reported symptom onset and other additional surveillance data, where we used only widely
available official reports of confirmed cases. Another mechanistic (Maier and Brockmann, 2020)
study confirmed the effectiveness of early containment strategies in Wuhan.
South Korea did not impose a nation-wide lockdown or closure of businesses, but at the very
early stage (when many cases linked to patient 31 were reported on February 20) conducted exten-
sive broad-based testing and detection (drive through tests started on February 26), rigorous contact
tracing, isolation of cases, and mobile phone tracking. Our results suggest that South Korea’s early
mitigation measures were also effective.
Italy’s initial mitigation strategies in the most affected areas reduced Rt from 3.73 to 1.92 in
20 days. To estimate the effect of the nation-wide lockdown as in a natural experiment, we require
local randomization and the continuity assumption. The former requires that characteristics of
subjects who are infected right before or after the lockdown are similar. Since in a very short time
period, whether a person is infected at time t or t+ 1 is likely to be random, local randomization is
likely to be valid. Continuity assumption refers to that the transmission rate before the lockdown
would be the same as the trend afterwards had the intervention not been implemented. Under this
assumption, the lockdown in Italy is not effective to further reduce the transmission speed (slopes
of a(t) are similar before and after lockdown on March 11). There were 10,149 cases reported in
Italy as of March 10, suggesting that the lockdown was placed after the wide community spread
had already occurred. Nevertheless, it is possible that without the lockdown the transmission rate
would have had increased, i.e., the lockdown enhanced and maintained the effect of quarantine for
two weeks. In fact, after two weeks of lockdown, we observe a loss of temporal effect so that Rt
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has remained around 1.0 for about 2-3 weeks before it starts to decrease again.
For the US, Rt was as high as 4.50 before the declaration of national emergency on March
13, but declines rapidly over a two-week period after March 13. Although the disease trend and
mitigation strategies vary across states in the US, since the declaration of national emergency,
many states have implemented social distancing and ban of large gathering. The large difference
before and two weeks after March 13 is likely due to states with large numbers of cases that
implemented state-wide stay-at-home orders (e.g., New York, New Jersey), which indicates that
these measures may be effective. Our model estimated a continued decrease in Rt from March
27 to May 1 but at a much slower rate (95.9% slower; Table 5.1, comparing a2 and a3 for the
US) when it approached 1.0. In China, centralized quarantine and treatment were implemented
when Rt was around 1.0 (Pan et al., 2020), which assisted in quick further reduction of Rt to
zero and final control of the epidemic. If the trend in US continues after May 1, the first wave
of epidemic will be controlled by July 26 (CI: July 9, August 27). However, after May 1 many
states enter a re-opening phase. If the guidelines on quarantine measures are relaxed so that the
temporal effect of quarantine measures is completely lost, the predicted total number of cases
is more than 2 million, with a long delay in controlling the epidemic (less than 100 cases by
November 19, and no new case by May, 2021). In an updated analysis which includes additional
observed data in May, the recentRt is near a constant between 1.1 and 1.2 from April 11 to May 29,
and the confidence interval suggests some possibility of an uptake of new cases (Supplementary
Material). These results suggest that the epidemic in the US is still not yet fully under control by
June 7, especially in certain states that present a consistent increase of daily new cases since re-
opening. Careful mitigation measures should be maintained to prevent an uptake in daily new cases
and another outbreak. These prediction results will be regularly updated at our Github website
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(https://github.com/COVID19BIOSTAT/covid19_prediction).
Other studies reported transmission between asymptomatic individuals (Li et al., 2020c), which
is not accounted for here. However, asymptomatic individuals can only be identified and con-
firmed by serological tests which are not widely available. When there is a delay in reporting
some symptomatic patients, the daily reported cases are a mixture of new symptomatic cases and
patients presenting after having had symptoms for a few days. In this case, the average number
of days to testing positive may be higher than the virus incubation period of 5.2 days. However,
as shown in our sensitivity analysis, the prediction of daily reported cases was not affected by
using a larger mean value for S(m), demonstrating robustness of the model. Our model does not
consider subject-specific covariates and focuses on predicting population-level quantities. Neither
have we considered borrowing information from multiple countries or state-level analysis for the
US, which are worthy of study in a mixed effects model framework. We do not consider prediction
of daily new deaths or hospitalizations. These data can be included to enhance the prediction of
new cases by linking the distribution of time to COVID symptom onsets, hospitalization, or death.
Lastly, we can consider a broader class of models for transmission rate a(t) to allow discontinu-
ity in both intercepts and slopes before and after an intervention under a regression discontinuity
design (Thistlethwaite and Campbell, 1960; Smith et al., 2015).
Despite these limitations, our study offers several implications. Implementing mitigation mea-
sures earlier in the disease epidemic reduces the disease transmission rate at a faster speed (South
Korea, China). Thus for regions at the early stage of disease epidemic, mitigation measures should
be introduced early. Nation-wide lockdown may not further reduce the speed of Rt reduction
compared to regional quarantine measures as seen in Italy. In countries where disease transmis-
sions have slowed down, lifting of quarantine measures may lead to a persistent transmission rate
102
delaying control of epidemic and thus should be implemented with caution and close monitoring.
Data sharing
All data and optimization codes are publicly available at our Github website: https://github.
com/COVID19BIOSTAT. The prediction will be updated regularly at this website. The model re-
sults are also included in the CDC ensemble modeling group to provide weekly forecasts to inform
national COVID response strategies (https://covid.cdc.gov/covid-data-tracker/
#forecasting_weeklydeaths; Ray et al. (2020)).
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Table 5.1: Model Estimated Parameters in Each Country
Country Parameter Estimate 95% CI
or Prediction∗
China t0(d) Jan 3 (17) (12, 21)∗∗
Training data: Jan 20 to Feb 4 a0 0.793 (0.68, 1.02)
Testing data: Feb 5 to May 10 a1 -0.693 (-1.13, -0.42)
Duration 44 (39, 55)
End date Mar 4 (Feb 28, Mar 15)
Total 58,415 (42,516, 133,083)
South Korea t0(d) Feb 11 (4) (1, 7)
Training data: Feb 15 to Mar 4 a0 1.363 (1.03, 1.98)
Testing data: Mar 5 to May 10 a1 -1.496 (-2.39, -0.96)
Duration 39 (37, 43)
End date Mar 25 (Mar 23, Mar 29)
Total 7,977 (7,307, 10,562)
Italy t0(d) Feb 10 (10) (4, 11)
Training data: Feb 20 to Apr 29 a0 0.789 (0.73, 1.10)
Testing data: Apr 30 to May 10 a1 -0.358 (-0.68, -0.26)
a2 -0.372 (-0.46, -0.31)
a3 0.061 (0.02, 0.12)
a4 -0.057 (-0.12, -0.01)
Duration 123 (103, 179)
End date Jun 22 (Jun 2, Aug 17)
Total 223,410 (216,848, 257,710)
United States t0(d) Feb 15 (6) (1, 4)
Training data: Feb 21 to May 1 a0 0.410 (0.34, 0.62)
Testing data: May 2 to May 10 a1 0.526 (0.23, 0.72)
a2 -1.031 (-1.24, -0.86)
a3 -0.042 (-0.06, -0.03)
Scenario 1: Continue current† Duration 156 (139, 188)
End date Jul 26 (Jul 9, Aug 27)
Total 1,626,950 (1,501,036, 1,918,602)
Scenario 2: 50% slower Duration 188 (163, 233)
after May 1 End date Aug 27 (Aug 2, Oct 11)
Total 1,731,992 (1,563,122, 2,113,294)
Scenario 3: 75% slower Duration 226 (190, 289)
after May 1 End date Oct 4 (Aug 29, Dec 5)
Total 1,832,291 (1,616,574, 2,324,552)
Scenario 4: 100% slower Duration‡ 272 (201, 448)
after May 1 Control date‡ Nov 19 (Sep 9, May 13 (2021))
Total‡ 2,084,235 (1,728,028, 3,094,518)
∗: t0 is the estimated date of the first undetected community infection; d is the estimated gap days between the first
undetected case and the first reported case; a0 is the transmission rate before the reported first case; a1, a2 and a3 are
rates of change of a(t) in each period measured as change per 21 days; “Duration” is the number of days from the
date of the first reported case to “End date”; “End date” is the date when predicted new case decreases to zero; “Total”
is the total number of predicted cases by the “End date”. ∗∗: CI for d. †: Scenario 1 assumes the transmission rate
decreases at the same rate (i.e., a3) after May 1; Scenarios 2 to 4 assume the relaxation of quarantine measures after
May 1 will lead to a slower decrease of transmission rate by 50%, 75% and 100% (complete loss of temporal effect
over time). ‡: Under scenario 4, “Duration” and “Control date” is defined by the date when the predicted daily new
case is less than 100 since the distribution of new cases has an extremely long tail (the end date defined by zero new




In this dissertation, we have developed several statistical methods to jointly model patients’ health
progression trajectories using longitudinal multi-domain biological and clinical data and to learn
dynamics of latent cortical activities using multi-channel EEG data. Our computationally effi-
cient methods can integrate data sources from different domains to inform heterogeneous disease
mechanisms and facilitate early diagnosis of neurological disorders.
In Chapter 2, we propose a nonlinear mixture model to fit ordinal markers jointly. The model
can estimate marker- and subject-specific sigmoidal progression trajectories and establish the time-
dependent order of deterioration occurrence to identify early progressive markers for assisting
diagnosis. It can also quantify the effect of subject characteristics (e.g., genetic background)
on the long-term disease trajectories. In Chapter 3, we extended the model to integrate multi-
ple domains of markers through a hierarchical multi-layer exponential family model. In addi-
tion to jointly estimating marker trajectories, our model includes a factor model component to
learn the lower-dimensional domain-specific factors and the shared factors across domains that
can cluster patients into more homogeneous subgroups. The above two chapters provide op-
portunities to examine disease impairments through interplay among various domains of mark-
ers. The models can be used to investigate important markers to improve criteria for clinical
diagnosis and evaluate treatment effects to accelerate drug development. In Chapter 4, we ana-
105
lyze multi-channel EEG data using a state space model to study the dynamics of brain activities.
Our model incorporates patient-specific characteristics and quantifies their effects on the evolu-
tion of latent sources. The model effectively removes noise in EEG data and characterizes dif-
ferent patterns of brain dynamics comparing clinical patients and healthy controls. In Chapter
5, in response to COVID-19 pandemic, we propose a survival convolution model to forecast in-
cident COVID-19 cases. Our model is a part of the CDC ensemble modeling group (https:
//covid.cdc.gov/covid-data-tracker/#forecasting_weeklydeaths) which
provides inputs to shape national COVID-related policies (Ray et al., 2020).
Several extensions can be considered in the future work. For modeling marker trajectories ac-
commodating heterogeneous patient subgroups, we can consider models that simultaneously allow
patient mixture groups in the latent factors or in the parameters describing marker trajectories. Be-
sides multivariate longitudinal data, we can also extend the model to jointly model time-to-event
critical events of clinical interests. For modeling complex non-stationary EEG data, the model can
be extended using the time-varying connectivity matrix or switching state space models. Moreover,
we can incorporate the existing knowledge of underlying physics and brain anatomy in the model
to learn more informative and interpretable latent states. For forecasting COVID incidence cases,
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S., Boonyasiri, A., Cucunubá, Z., Cuomo-Dannenburg, G., et al. (2020). Impact of non-
pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.
Imperial College London COVID-19 Reports.
Flaxman, S., Mishra, S., Gandy, A., Unwin, H. J. T., Coupland, H., Mellan, T. A., Zhu, H., Berah,
T., Eaton, J. W., Guzman, P. N., et al. (2020). Estimating the number of infections and the impact
of non-pharmaceutical interventions on COVID-19 in European countries: technical description
update. arXiv preprint arXiv:2004.11342.
Ganyani, T., Kremer, C., Chen, D., Torneri, A., Faes, C., Wallinga, J., and Hens, N. (2020).
Estimating the generation interval for COVID-19 based on symptom onset data. medRxiv.
110
Gates, B. (2020). Responding to COVID-19—a once-in-a-century pandemic? New England
Journal of Medicine, 382(18):1677–1679.
Gelb, D., Oliver, E., and Gilman, S. (1999). Diagnostic criteria for parkinson disease. Archives of
neurology, 56(1):33.
Ghahramani, Z. and Hinton, G. E. (2000). Variational learning for switching state-space models.
Neural computation, 12(4):831–864.
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., Poewe,
W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008). Movement disorder society-sponsored
revision of the unified parkinson’s disease rating scale (mds-updrs): scale presentation and clini-
metric testing results. Movement disorders: official journal of the Movement Disorder Society,
23(15):2129–2170.
Guo, Z.-G., Sun, G.-Q., Wang, Z., Jin, Z., Li, L., and Li, C. (2020). Spatial dynamics of an
epidemic model with nonlocal infection. Applied Mathematics and Computation, 377:125158.
Hartley, D. M. and Perencevich, E. N. (2020). Public health interventions for COVID-19: emerging
evidence and implications for an evolving public health crisis. JAMA.
Hassan, M. and Wendling, F. (2018). Electroencephalography source connectivity: toward high
time/space resolution brain networks. arXiv preprint arXiv:1801.02549.
Haufe, S., Nikulin, V. V., Ziehe, A., Müller, K.-R., and Nolte, G. (2008). Combining sparsity and
rotational invariance in eeg/meg source reconstruction. NeuroImage, 42(2):726–738.
Haufe, S., Tomioka, R., Dickhaus, T., Sannelli, C., Blankertz, B., Nolte, G., and Müller, K.-R.
111
(2011). Large-scale eeg/meg source localization with spatial flexibility. NeuroImage, 54(2):851–
859.
Iddi, S., Li, D., Aisen, P. S., Rafii, M. S., Litvan, I., Thompson, W. K., and Donohue, M. C.
(2018). Estimating the evolution of disease in the parkinson’s progression markers initiative.
Neurodegenerative Diseases, 18(4):173–190.
IHME, Murray, C. J., et al. (2020). Forecasting COVID-19 impact on hospital bed-days, ICU-days,
ventilator-days and deaths by US state in the next 4 months. MedRxiv.
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Appendix A: Appendix to Chapter 2
A.1 EM Algorithm
A.1.1 E-Step
To compute the conditional expectation of the complete log-likelihood given the current parameters
and observed data, it is sufficient to get Ê(Qik), Ê(Wi) and Ê[(1 − Qik)g(Wi)]. Since X and t
are observed and fixed, we omit them in the equations for simplicity.
P̂ (Qik = 1|Wi) = P (Qik = 1|Wi,Yi = yi)
where
















P̂ (Wi) = P (Wi|Yi = yi) =
P (Yi = yi|Wi)∫
Wi
P (Yi = yi|Wi)f(Wi)dWi
f(Wi),
where





































Here, xj is the nodes, wj is the associated weight, and M is number of simulated nodes. xj and wj
can be easily obtained using the R package statmod (Smyth et al., 2017). We choose M = 20 in








P̂ (Qik = 1|Wi)P̂ (Wi)dWi, using h(Wi) =
P (Yi = yi|Wi)P̂ (Qik = 1|Wi)∫
Wi






P̂ (Wi)WidWi, using h(Wi) =
P (Yi = yi|Wi)Wi∫
Wi





f(Wi)P̂ (Wi)[1− P̂ (Qik = 1|Wi)]dWi, (A3)
using h(Wi) =
P (Yi = yi|Wi)(1− P̂ (Qik = 1|Wi))g(Wi)∫
Wi
P (Yi = yi|Wi)f(Wi)dWi
,
where g(·) is any arbitrary function of Wi.
A.1.2 M-Step
For γk, χ̃k and δc, there are no analytical solutions. We apply 1-step Newton-Raphson to approxi-















































































































































Other pairwise Hessian matrices have very similar forms and are omit here.
A.2 Tables
123
Table A.1: Estimates for progression rate and inflection point at each level for LRRK2-G2019S
carriers and non-carriers
Carriers Non-carriers
b µ† µ− δ2/b‡ µ− δ3/b∗ b µ† µ− δ2/b‡ µ− δ3/b∗
NP2FREZ -0.21 75.2 87.11 90.25 -0.44 69.19 74.75 78.16
NP3RISING -0.2 73.16 85.87 89.22 -0.75 68.54 71.76 73.73
NP3GAIT -0.15 66.25 83.28 87.76 -0.4 64.27 70.35 74.08
NP3FRZGT -0.4 80.2 86.51 88.17 -0.96 71.63 74.15 75.7
NP3PSTBL -0.27 73.34 82.66 85.12 -0.76 68.14 71.33 73.28
NP3POSTR -0.19 67.69 80.63 84.03 -0.48 64.37 69.46 72.58
NP3SPCH -0.1 70.21 95.76 102.49 -0.26 64.59 73.85 79.52
NP3FACXP -0.08 55.81 88 96.49 -0.15 57.22 73.03 82.73
NP3BRADY∗∗ -0.1 57.72 83.51 90.31 -0.35 61.07 68.02 72.28
∗∗ Labels for the markers: NP2FREZ, Freezing; NP3RISNG, Arising from chair; NP3GAIT, Gait; NP3FRZGT, Freez-
ing of gait; NP3PSTBL, Postural stability; NP3POSTR, Posture; NP3SPCH, Speech; NP3FACXP, Facial expression;
NP3BRADY, Global spontaneity of movement.
† Inflection points for P (Y ≤ 1)
‡ Inflection points for P (Y ≤ 2)
∗ Inflection points for P (Y ≤ 3)
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Table A.2: The parameter estimates of simulation data under Scenario I†
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10
b -0.05 -0.05 -0.2 -0.2 -0.2 -0.4 -0.4 -0.4 -0.6 -0.6
Estimate -0.050 -0.050 -0.201 -0.199 -0.199 -0.400 -0.395 -0.384 -0.604 -0.592
Empirical s.d 0.002 0.003 0.007 0.009 0.013 0.016 0.020 0.028 0.035 0.045
Bootstrap s.d 0.003 0.003 0.007 0.009 0.012 0.018 0.020 0.028 0.033 0.046
CI coverage (%) 95 93 92 91 89 95 91 94 90 94
µ 50 70 50 60 70 50 70 60 70 50
Estimate 50.421 73.567 50.286 61.714 73.441 50.020 71.697 63.399 70.038 51.711
Empirical s.d 1.351 3.371 0.466 1.466 2.997 0.286 1.533 3.068 0.243 1.438
Bootstrap s.d 1.256 2.582 0.420 1.242 2.446 0.280 1.181 2.468 0.228 1.218
CI coverage (%) 96 98 91 100 100 95 100 100 91 100
χ 0.5 10 0.5 5 10 0 5 10 0 5
Estimate 0.539 10.607 0.520 5.225 10.520 0.036 5.280 10.452 0.029 5.248
Empirical s.d 0.376 1.405 0.147 0.560 1.207 0.056 0.598 1.190 0.044 0.600
Bootstrap s.d 0.338 1.049 0.142 0.417 0.848 0.051 0.380 0.803 0.043 0.389
CI coverage (%) 95 96 93 94 95 98 91 94 98 93
η1 -2 -2 -2 -0.3 -0.3 -2 -2 -0.3 -2 -0.3
Estimate -2.109 -2.173 -1.965 -0.345 -0.304 -2.017 -2.054 -0.350 -2.054 -0.312
Empirical s.d 0.395 0.723 0.324 0.223 0.284 0.340 0.352 0.261 0.357 0.213
Bootstrap s.d 0.497 2.104 0.340 0.227 0.282 0.366 0.441 0.249 0.430 0.217
CI coverage (%) 92 88 94 92 93 90 97 94 91 93
η2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Estimate 0.573 0.625 0.447 0.561 0.533 0.397 0.569 0.514 0.485 0.538
Empirical s.d 0.512 0.626 0.474 0.363 0.384 0.451 0.508 0.388 0.517 0.337
Bootstrap s.d 0.662 1.298 0.486 0.347 0.397 0.511 0.579 0.358 0.703 0.330
CI coverage (%) 97 90 94 93 94 94 95 90 96 94
η3 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5
Estimate -0.519 -0.575 -0.505 -0.502 -0.506 -0.520 -0.484 -0.528 -0.460 -0.521
Empirical s.d 0.199 0.352 0.218 0.175 0.244 0.206 0.242 0.204 0.225 0.168
Bootstrap s.d 0.249 0.808 0.216 0.180 0.222 0.223 0.256 0.196 0.244 0.174
CI coverage (%) 99 95 90 97 93 93 93 90 94 96
δ2 δ3 θ1 θ2
δ‡ 2 3 θ‡ -1 2
Estimate 1.983 2.988 Estimate -1.275 1.934
Empirical s.d 0.088 0.115 Empirical s.d 0.210 0.194
Bootstrap s.d 0.075 0.100 Bootstrap s.d 0.275 0.202
CI coverage (%) 95 86 CI coverage (%) 100 95
† In Scenario I, we simulate 100 data sets with each containing 200 subjects. The proposed model is used to jointly estimate
the parameters. The average parameter estimates (Estimate) is reported, with the true parameter values in the shaded rows.
The Empirical s.d is the standard deviation of the estimates from the 100 data sets. For each simulated data set, 200 bootstrap
replicates are created to compute the average standard deviation of the estimates (Bootstrap s.d) and the coverage probability of
95% confidence intervals (CI coverage).
‡δ and θ are the parameters shared across the 10 markers. All the other parameters are of dimension 10 with distinct values for
the 10 markers. δ1 is fixed at 0 for ease of identification.
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Table A.3: The parameter estimates of simulation data under Scenario II†
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10
b -0.05 -0.05 -0.20 -0.20 -0.20 -0.40 -0.40 -0.40 -0.60 -0.60
Estimate -0.050 -0.050 -0.199 -0.199 -0.196 -0.399 -0.394 -0.383 -0.601 -0.585
Empirical s.d 0.002 0.002 0.006 0.007 0.007 0.011 0.013 0.018 0.025 0.034
Bootstrap s.d 0.002 0.002 0.005 0.006 0.008 0.012 0.014 0.019 0.022 0.031
CI coverage (%) 96 95 89 94 96 98 94 92 92 91
µ 50 70 50 60 70 50 70 60 70 50
Estimate 50.252 72.293 50.151 61.125 72.248 50.046 71.072 62.229 70.044 51.082
Empirical s.d 0.910 2.532 0.343 1.245 2.626 0.224 1.300 2.722 0.158 1.270
Bootstrap s.d 0.883 1.985 0.303 0.973 1.941 0.198 0.940 1.962 0.161 0.970
CI coverage (%) 98 98 93 100 98 88 99 99 93 100
χ 0.5 10 0.5 5 10 0 5 10 0 5
Estimate 0.565 10.263 0.511 5.151 10.329 0.027 5.143 10.263 0.025 5.145
Empirical s.d 0.292 0.879 0.103 0.362 0.800 0.044 0.362 0.729 0.036 0.344
Bootstrap s.d 0.266 0.725 0.099 0.285 0.577 0.037 0.258 0.560 0.032 0.268
CI coverage (%) 95 96 95 95 95 94 96 97 98 94
η1 -2 -2 -2 -0.3 -0.3 -2 -2 -0.3 -2 -0.3
Estimate -2.020 -2.042 -2.032 -0.327 -0.316 -2.018 -2.028 -0.284 -2.026 -0.294
Empirical s.d 0.253 0.319 0.243 0.175 0.185 0.253 0.280 0.176 0.272 0.165
Bootstrap s.d 0.255 0.314 0.241 0.162 0.199 0.239 0.282 0.175 0.261 0.154
CI coverage (%) 93 96 94 90 97 96 96 95 90 93
η2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Estimate 0.529 0.494 0.490 0.506 0.518 0.524 0.503 0.462 0.515 0.478
Empirical s.d 0.319 0.398 0.297 0.244 0.245 0.282 0.343 0.227 0.355 0.207
Bootstrap s.d 0.327 0.371 0.310 0.229 0.259 0.309 0.343 0.240 0.338 0.221
CI coverage (%) 95 94 94 93 93 96 92 92 92 92
η3 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5
Estimate -0.524 -0.519 -0.505 -0.525 -0.508 -0.522 -0.517 -0.486 -0.526 -0.504
Empirical s.d 0.169 0.209 0.155 0.133 0.139 0.138 0.186 0.126 0.149 0.119
Bootstrap s.d 0.158 0.193 0.154 0.126 0.158 0.153 0.181 0.139 0.167 0.119
CI coverage (%) 89 91 92 92 97 96 96 96 95 93
δ2 δ3 θ1 θ2
δ‡ 2 3 θ‡ -1 2
Estimate 1.980 2.958 Estimate -1.179 1.951
Empirical s.d 0.064 0.081 Empirical s.d 0.216 0.135
Bootstrap s.d 0.052 0.071 Bootstrap s.d 0.205 0.134
CI coverage (%) 93 88 CI coverage (%) 97 99
† In Scenario II, we simulate 100 data sets with each containing 400 subjects. The proposed model is used to jointly estimate
the parameters. The average parameter estimates (Estimate) is reported, with the true parameter values in the shaded rows.
The Empirical s.d is the standard deviation of the estimates from the 100 data sets. For each simulated data set, 200 bootstrap
replicates are created to compute the average standard deviation of the estimates (Bootstrap s.d) and the coverage probability of
95% confidence intervals (CI coverage).
‡δ and θ are the parameters shared across the 10 markers. All the other parameters are of dimension 10 with distinct values for
the 10 markers. δ1 is fixed at 0 for ease of identification.
126
Table A.4: The parameter estimates of simulation data under Scenario III†
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10
b -0.05 -0.05 -0.20 -0.20 -0.20 -0.40 -0.40 -0.40 -0.60 -0.60
Estimate -0.050 -0.047 -0.199 -0.192 -0.194 -0.392 -0.396 -0.353 -0.598 -0.577
Empirical s.d 0.002 0.006 0.008 0.014 0.011 0.017 0.024 0.028 0.036 0.056
Bootstrap s.d 0.002 0.006 0.006 0.019 0.013 0.022 0.025 0.029 0.041 0.059
CI coverage (%) 94 80 34 88 91 97 95 75 98 93
µ 50 70 50 60 70 50 70 60 70 50
Estimate 50.129 69.767 50.046 60.562 70.105 50.206 69.981 61.898 70.112 50.265
Empirical s.d 1.115 2.491 0.523 1.158 1.369 0.284 0.585 2.105 0.281 0.826
Bootstrap s.d 1.048 3.187 0.382 2.744 2.377 0.314 0.755 1.676 0.245 0.834
CI coverage (%) 96 91 72 97 96 91 97 96 88 97
χ 0.5 10 0.5 5 10 0 5 10 0 5
Estimate 1.065 7.921 0.432 4.848 9.758 0.155 4.953 10.110 0.054 4.971
Empirical s.d 1.308 4.020 0.377 0.721 0.967 0.217 0.337 0.946 0.099 0.337
Bootstrap s.d 0.581 3.740 0.093 1.350 0.957 0.203 0.318 0.834 0.183 0.390
CI coverage (%) 58 85 13 99 88 100 92 92 100 95
η1 -2 -2 -2 -0.3 -0.3 -2 -2 -0.3 -2 -0.3
Estimate -2.018 -1.952 -2.030 -0.324 -0.310 -2.019 -2.004 -0.330 -2.028 -0.290
Empirical s.d 0.253 0.175 0.277 0.164 0.298 0.282 0.355 0.276 0.151 0.143
Bootstrap s.d 0.255 0.168 0.302 0.153 0.312 0.309 0.337 0.281 0.180 0.152
CI coverage (%) 95 85 91 89 95 95 94 94 91 92
η2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Estimate 0.533 0.423 0.488 0.501 0.515 0.524 0.488 0.498 0.514 0.472
Empirical s.d 0.378 0.207 0.195 0.320 0.242 0.327 0.207 0.156 0.138 0.149
Bootstrap s.d 0.357 0.233 0.192 0.329 0.231 0.352 0.219 0.153 0.152 0.167
CI coverage (%) 96 89 93 94 93 96 96 90 91 92
η3 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5
Estimate -0.517 -0.448 -0.503 -0.524 -0.509 -0.521 -0.505 -0.513 -0.525 -0.502
Empirical s.d 0.243 0.253 0.273 0.401 0.271 0.241 0.168 0.133 0.192 0.119
Bootstrap s.d 0.242 0.239 0.259 0.376 0.277 0.250 0.160 0.130 0.193 0.118
CI coverage (%) 88 83 90 93 97 94 93 96 96 92
δ2 δ3 θ1 θ2
δ‡ 2 3 θ‡ -1 2
Estimate 1.878 2.814 Estimate -0.891 1.439
Empirical s.d 0.082 0.114 Empirical s.d 0.294 0.285
Bootstrap s.d 0.086 0.191 Bootstrap s.d 0.158 0.213
CI coverage (%) 46 34 CI coverage (%) 84 0
† In Scenario III, we simulate 100 data sets with each containing 400 subjects. The proposed model is used separately for each
marker to estimate the parameters. The average parameter estimates (Estimate) is reported, with the true parameter values in the
shaded rows. The Empirical s.d is the standard deviation of the estimates from the 100 data sets. For each simulated data set,
200 bootstrap replicates are created to compute the average standard deviation of the estimates (Bootstrap s.d) and the coverage
probability of 95% confidence intervals (CI coverage).
‡We report the estimators of θ and δ as the averages of individually estimated values across 10 markers. All the other parameters
are of dimension 10 with distinct values for the 10 markers. δ1 is fixed at 0 for ease of identification.
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Appendix B: Appendix to Chapter 4















































































































































Figure B.2: Boxplots of biases of the estimates A,α and Θ from 100 simulated data sets generated
from the model with m = 2, α1 = −0.05, α2 = −0.08 and σ2i = 5, 1.
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Figure B.4: The estimated 3-dimensional latent states Mj|j−1 for each visual stimulus averaged
across cases or controls. The EEG outcomes in FP, AF, F and FC lobes are mainly influenced by
the green latent states while CP, P, PO and O lobes mainly rely on the pink states.
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C2	
Figure B.5: Fitted EEG outcomes under visual stimulus C2 when assuming L = 1, 2, 3 and 4
(rows). Each trajectory represents a fitted EEG channel averaged across 77 cases (left) or 45
controls (right).
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Appendix C: Appendix to Chapter 5
C.1 Model Estimation, Inference, and Updated Results
We propose a parsimonious survival-convolution model for predicting key statistics of COVID-
19 epidemics (e.g., daily new cases) and evaluate public health intervention effect. We model
the transmission rate a(t) as a non-negative piece-wise linear function (linear spline and assume
a(t) ≥ 0). For China and South Korea, a(t) is given as follows:
a(t) =

a+0 t < t1
(a0 + a1(t− t1))+ t ≥ t1
, (C.1)
where x+ = max(x, 0) and t1 is the calendar time of reporting the first case. That is, before the
first case is reported, the public is unaware and the infection is latent, so the transmission rate is
assumed to be a constant; however, once the first case is reported, the public is alerted and various
response strategies are gradually introduced and take effect, so that we expect the transmission rate
will decrease (i.e., a1 ≤ 0). In this simple model, there are three parameters that will be estimated
from data, including t0 (the date of the first case), a0, and a1.
When a massive public health intervention (e.g., nation-wide lockdown) is introduced at some
particular date, we further add an additional linear function after this date and introduce a new
slope parameter. Thus, the difference in the rate of change in a(t) before and after an intervention
reflects its effect on reducing disease transmission (i.e., “flattening the curve”). Furthermore, since
the intervention effect may diminish over time, we introduce slope parameters two weeks after
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the intervention (considering the incubation period as 14 days) to capture the longer-term effect.
Therefore, for Italy and US we place additional knots at t2 (the date of national lockdown for Italy
and the declaration of national emergency for US) and t3 (two weeks after t2). The transmission
rate is modeled as:
a(t) =

a+0 t < t1,
(a0 + a1(t− t1))+ t1 ≤ t < t2,
(a0 + a1(t2 − t1) + a2(t− t2))+ t2 ≤ t < t3,
(a0 + a1(t2 − t1) + a2(t3 − t2) + a3(t− t3))+ t ≥ t3.
(C.2)
A long observational period is available for Italy. We place another knot four weeks after t2 to
capture potential long-term effect of the intervention.
Let θ denote all parameters in the transmission rate a(t) (e.g, a0, · · · , ak in equations s1 and
s2) and t0. We divide the reported daily new cases into training data for estimating parameters and
testing data for validation. Denote by Yo(t1), Yo(t1 + 1), Yo(t1 + 2), ...., Yo(t2), the training data
consisting of the daily new cases reported from the date of the first reported case, t1, to the last
date in the training set, t2. To estimate θ using the training data, first note that the number of daily
confirmed tested positive cases is a measure of the number of infected cases out of transmission due
to a positive COVID test (i.e., Y (t)) observed with error (e.g., reporting error, tested positive but not
practicing social distancing). Second, it is plausible that the error variability is proportional to the
underlying true number of cases (e.g., holds for Poisson random variables). Our model is Yo(t) =
Y (t) +
√
Y (t)ε(t), where ε(t) represents a residual term. Let Y (t; θ) denote the predicted new
case number at day t for a given θ using recursive equations in (1) and (2) in the main manuscript.
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to estimate θ. The square-root transformation is applied to the daily cases since it is a variance
stabilizing transformation for Poisson counts. Computationally, we perform a grid search to esti-
mate t0. For each t0, we apply a gradient-based optimizer with adaptive learning rate (i.e., Adam
Kingma and Ba (2014)) to obtain other parameters. The algorithm is implemented in Tensorflow
(Abadi et al., 2015). We let θ̂ be the minimizer of (C.3). With θ̂, we can use equations (1) and (2)
in the main manuscript to predict any new daily cases in future dates. Furthermore, by comparing
the estimated a(t) (and correspondingly, Rt) before and after a public health intervention is imple-
mented, we can estimate the intervention effect in terms of the change of transmission rates under
the longitudinal pre- and post-intervention design.
For statistical inference such as obtaining confidence intervals of predicted numbers or esti-
mated intervention effects, we assume that the standardized residuals,
[Yo(t)− Y (t; θ)] /
√
Y (t; θ), are exchangeable. Thus, permutation method can be used. We per-
mute the estimated residuals and reconstruct observed cases by adding permuted residuals mul-
tiplied by the square-root of the observed case numbers. We repeat this process 500 times and
re-analyze each set of permuted data to yield a set of estimates for θ, the corresponding set of pre-
dictions for Y (t; θ) and estimated intervention effects. We obtain 95% confidence intervals using
empirical quantiles of the estimates under permutation.
To model the distribution of time to symptom onset since infection, we use the existing knowl-
edge of SARS-CoV-2 virus incubation period. Previous work (Li et al., 2020b) indicates that the
incubation period for SARS-CoV-2 has an average of 5.2 days, and the longest time to symptom
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onset since infection was reported up to 21 days. Thus, we model the survival function of present-
ing COVID-19 symptoms as an exponential distribution with a mean of 5.2 truncated at 21, and
use this distribution to approximate S(m) in equations (1) and (2) in the main manuscript. In a set
of sensitivity analyses, we examine the influence of using a longer mean parameter of this distri-
bution. For the sensitivity analysis of the US, we use a mean value of 5.2 + 4 = 9.2 (an average of
4-day lag between symptom onset and reporting of daily new cases was observed in a CDC report
(Centers for Disease Control, 2020)). For the sensitivity analysis of Italy, we use a mean value of
5.2 + 5.3 = 10.5 days (an average of 5.3-day lag between symptom onset and reporting of daily
new cases was observed in Italy (Riccardo et al., 2020)). The results in Figure C.2 show that the
fitted curves of daily new cases under different parameters of S(m) are identical for US. For Italy,
the fitted curves over training data period are almost identical and there is a slight difference at the
tail (Figure C.3).
We update the analysis of US epidemic using more training data from Feb 21 to May 29. The
knots are placed on March 13 (national emergency) and every two weeks (length of incubation
period) after that until April 24 to account for potential changes in the transmission rates. We leave
5 weeks of training data before May 29 to robustly determine the trend of the transmission rate for
future predictions. The observed training and testing data (May 30 to June 6) are plotted in Figure
C.4A. With 500 permutation samples, the 95% confidence interval is included for the testing data
after May 30. The effective reproduction numberRt is calculated using the piecewise transmission
rate and plotted in Figure C.4B. Similar to Figure 3B in the main manuscript, the Rt decreases at
a faster rate after the declaration of national emergency on March 13, but slows down when Rt
is closer to 1.0. Recently, Rt is near a constant between 1.1 and 1.2 without a clear evidence of
decreasing. Although there is a chance to expect less than 100 daily new cases by November 8 this
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year (with a predicted total number of cases as 2,714,972), the confidence interval suggests some
possibility that the daily cases will start to increase again. In fact, some states have experienced
an increasing trend in daily new cases since re-opening (e.g., California, Texas, North Carolina).
Given recent data, we can see that the US is still in the midst of the epidemic by June 7, 2020,
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(d)
Figure C.1: Latent and confirmed cases on each day in each country. Number of latent cases on day
t (i.e., estimated M(t)− Y (t)) includes all pre-symptomatic cases infected k days before but have
not been detected by day t. Solid lines separate observed number of cases and predicted number






































































used in model fitting
Testing data 
not included in model fitting Predicted Predicted (sensitivity)
Figure C.2: Sensitivity analysis of the US. Observed and predicted daily new cases comparing
using an exponential distribution with a mean of 5.2 (grey) and with a mean of 9.2 (orange).
First dashed line indicates the declaration of national emergency (March 13). Second dashed line
indicates two weeks after (March 27). Training data: February 21 to May 1; Testing data: May 2












































































used in model fitting
Testing data 
not included in model fitting Predicted Predicted (sensitivity)
Figure C.3: Sensitivity analysis of Italy. Observed and predicted daily new cases comparing using
an exponential distribution with a mean of 5.2 (grey) and with a mean of 10.5 (orange). First
dashed line indicates the national lockdown (March 11). Second and third dashed lines indicate
two weeks after. Training data: February 20 to April 29; Testing data: April 30 to May 10. Fitted
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Figure C.4: United States: observed and predicted daily new cases, 95% confidence intervals.
First dashed line indicates the declaration of national emergency (March 13). The second to fourth
dashed lines indicate every two weeks after (March 27). Training data: February 21 to May 29
(11 weeks after declaring national emergency); Testing data: May 30 to June 6. (A) Observed and
predicted daily new cases. (B) Effective reproduction number Rt.
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